Master Alliance Provisions Guide (MAPGuide)

Search Results For:

  • No search criteria provided
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
Advance Purchase Agreement for the Development, Production, Advance Purchase and Supply of a Covid-19 Vaccine for EU Member States with CureVac
2020
Government
Pharmaceutical manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Advance Purchase Agreement for the Production, Purchase and Supply of a Covid-19 Vaccine in the European Union with AstraZeneca
2020
Government
Pharmaceutical manufacturer
Vaccine manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Aridis-PATH Vaccine Formulation Agreement
2007
Biotechnology company
Product development partnership
Vaccine
Early clinical (through Phase 2)
AUTM Model Inter-Institutional Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Award Contract No. W911QY20C0100, by and between ModernaTX, Inc. and the Department of Defense
2020
Government
Multinational pharmaceutical company
Vaccine manufacturer
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Boston University Startup Exclusive License
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
CARB-X Research Subaward Agreement (for-profit)
2019
Funder
General Industry
Device
Diagnostic
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
CAVD Data & Materials Sharing Agreement
2006
Academic institution
Funder
General Industry
Government
Other nonprofit
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
CEPI CfP3i Template Funding Agreement
2018
Funder
Vaccine
Preclinical
Early clinical (through Phase 2)
Collaboration and License Agreement between Sanofi and Translate Bio, as Amended
2020
Biotechnology company
Multinational pharmaceutical company
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Ebola WHO-Manufacturer LOA (Annex)
2015
Multilateral organization
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
EDCTP2 Policy on Clinical Trials
2018
Funder
Device
Diagnostic
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Funder Development Partnering Agreement
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation Open Access Policy
2015
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation Sample Terms & Conditions
2019
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gilead-Indian Manufacturers HCV License Agreement
2014
Multinational pharmaceutical company
Pharmaceutical manufacturer
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Global Access Commitment & Humanitarian License
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 1 Model Grant Agreement
2011
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 2 JU Model Consortium Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Lambert Agreement D
2019
Academic institution
General Industry
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Merck-BSC License Collaboration Agreement
2014
Biotechnology company
Multinational pharmaceutical company
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Moderna – BARDA Agreement (Contract No.75A50122C00034 for Development of an mRNA Vaccine for Sars-Cov-2)
2020
Government
Multinational pharmaceutical company
Vaccine manufacturer
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
MPP-AbbVie License Agreement (LPV r)
2016
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
MPP-AbbVie Sublicense Agreement
2014
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
MPP-BMS-Aurobindo Sublicense Agreement
2016
Multinational pharmaceutical company
Other nonprofit
Pharmaceutical manufacturer
Drug
Commercialization
MPP-BMS Sublicense & Tech Transfer Agreement
2017
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
MPP-Gilead License Agreement
2011
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
MPP-Pfizer License Agreement (Sutezolid)
2019
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
MPP-Univ. of Liverpool License Agreement
2015
Academic institution
Other nonprofit
Device
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
MPP-ViiV License Agreement
2016
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
NIH Model License Agreement for Use by Non-Profit
2017
Government
Other nonprofit
Product development partnership
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Novavax–US Army Statement of Work for Rapid (WF10) Advanced Research & Development to Large Scale Manufacturing of NVX-CoV-2373 as a Vaccine for SARS-CoV-2 Coronavirus, under the Base Agreement between Novavax and Advanced Technology International
2020
Government
Pharmaceutical manufacturer
Vaccine manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Redacted Collaboration Agreement
2016
Academic institution
General Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Regeneron - ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
2020
Government
Pharmaceutical manufacturer
Drug
Late clinical (Phase 3)
Commercialization
Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
2020
Government
Multinational pharmaceutical company
Pharmaceutical manufacturer
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Ten Principles for Socially Responsible Licensing
2019
Academic institution
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Mutual Confidential Disclosure Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Project Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Standard Framework MoU
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Material Transfer Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => 
    [filters] => Array
        (
        )

    [child_filters] => Array
        (
        )

    [agreement_args] => 
    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
        )

    [text_agreement_args] => 
    [text_provision_args] => 
    [agreement_ids] => Array
        (
        )

    [agreement_q_rslts] => 
    [provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [s] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT   wpry_posts.* FROM wpry_posts  WHERE 1=1  AND wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')  ORDER BY wpry_posts.post_date DESC 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 2824
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:39:49
                            [post_date_gmt] => 2021-04-16 16:39:49
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 16:39:49
                            [post_modified_gmt] => 2021-04-16 16:39:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2824
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 2823
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:17:11
                            [post_date_gmt] => 2021-04-16 16:17:11
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 16:17:11
                            [post_modified_gmt] => 2021-04-16 16:17:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2823
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 2822
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:09:31
                            [post_date_gmt] => 2021-04-16 16:09:31
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 16:09:31
                            [post_modified_gmt] => 2021-04-16 16:09:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2822
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 2821
                            [post_author] => 5
                            [post_date] => 2021-04-16 12:55:04
                            [post_date_gmt] => 2021-04-16 12:55:04
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 12:55:04
                            [post_modified_gmt] => 2021-04-16 12:55:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2821
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 2820
                            [post_author] => 5
                            [post_date] => 2021-04-16 12:44:14
                            [post_date_gmt] => 2021-04-16 12:44:14
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 12:44:14
                            [post_modified_gmt] => 2021-04-16 12:44:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2820
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 2819
                            [post_author] => 5
                            [post_date] => 2021-04-16 12:12:32
                            [post_date_gmt] => 2021-04-16 12:12:32
                            [post_content] => 
                            [post_title] => Regeneron - ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 12:15:57
                            [post_modified_gmt] => 2021-04-16 12:15:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2819
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 2744
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:12:35
                            [post_date_gmt] => 2021-03-30 15:12:35
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-30 15:12:35
                            [post_modified_gmt] => 2021-03-30 15:12:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 2749
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:10:16
                            [post_date_gmt] => 2021-03-30 15:10:16
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-30 15:10:16
                            [post_modified_gmt] => 2021-03-30 15:10:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2749
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 2748
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:05:46
                            [post_date_gmt] => 2021-03-30 15:05:46
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 2748
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-30 15:06:12
                            [post_modified_gmt] => 2021-03-30 15:06:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2748
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 2740
                            [post_author] => 5
                            [post_date] => 2021-03-30 14:54:54
                            [post_date_gmt] => 2021-03-30 14:54:54
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-30 14:54:54
                            [post_modified_gmt] => 2021-03-30 14:54:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2740
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 2743
                            [post_author] => 5
                            [post_date] => 2021-03-24 15:11:40
                            [post_date_gmt] => 2021-03-24 15:11:40
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-24 15:11:40
                            [post_modified_gmt] => 2021-03-24 15:11:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2743
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 2742
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:37:07
                            [post_date_gmt] => 2021-03-24 13:37:07
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-24 13:37:07
                            [post_modified_gmt] => 2021-03-24 13:37:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2742
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 2741
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:32:55
                            [post_date_gmt] => 2021-03-24 13:32:55
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-24 13:32:55
                            [post_modified_gmt] => 2021-03-24 13:32:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2741
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 2739
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:12:14
                            [post_date_gmt] => 2021-03-24 13:12:14
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-24 13:12:14
                            [post_modified_gmt] => 2021-03-24 13:12:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2739
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 2738
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:04:24
                            [post_date_gmt] => 2021-03-24 13:04:24
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-24 13:04:24
                            [post_modified_gmt] => 2021-03-24 13:04:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2738
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 2737
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:00:46
                            [post_date_gmt] => 2021-03-24 13:00:46
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-24 13:00:46
                            [post_modified_gmt] => 2021-03-24 13:00:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2737
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 2736
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:15:15
                            [post_date_gmt] => 2021-03-23 18:15:15
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-23 18:15:15
                            [post_modified_gmt] => 2021-03-23 18:15:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2736
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 2735
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:05:28
                            [post_date_gmt] => 2021-03-23 18:05:28
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-23 18:05:28
                            [post_modified_gmt] => 2021-03-23 18:05:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2735
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 2734
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:01:22
                            [post_date_gmt] => 2021-03-23 18:01:22
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-23 18:01:38
                            [post_modified_gmt] => 2021-03-23 18:01:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2734
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 2543
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:15:58
                            [post_date_gmt] => 2021-03-12 18:15:58
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 18:15:58
                            [post_modified_gmt] => 2021-03-12 18:15:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2543
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 2540
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:12:48
                            [post_date_gmt] => 2021-03-12 18:12:48
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 18:12:48
                            [post_modified_gmt] => 2021-03-12 18:12:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2540
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 2541
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:11:14
                            [post_date_gmt] => 2021-03-12 18:11:14
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 18:11:14
                            [post_modified_gmt] => 2021-03-12 18:11:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2541
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 2542
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:21:07
                            [post_date_gmt] => 2021-03-12 14:21:07
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 15:00:22
                            [post_modified_gmt] => 2021-03-12 15:00:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2542
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 2544
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:16:06
                            [post_date_gmt] => 2021-03-12 14:16:06
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 14:16:06
                            [post_modified_gmt] => 2021-03-12 14:16:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2544
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 2545
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:14:38
                            [post_date_gmt] => 2021-03-12 14:14:38
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 14:14:38
                            [post_modified_gmt] => 2021-03-12 14:14:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2545
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 2546
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:13:16
                            [post_date_gmt] => 2021-03-12 14:13:16
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 14:13:16
                            [post_modified_gmt] => 2021-03-12 14:13:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2546
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 2547
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:58:55
                            [post_date_gmt] => 2021-03-12 13:58:55
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 14:10:14
                            [post_modified_gmt] => 2021-03-12 14:10:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2547
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 2548
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:55:59
                            [post_date_gmt] => 2021-03-12 13:55:59
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 13:55:59
                            [post_modified_gmt] => 2021-03-12 13:55:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2548
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 2549
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:50:41
                            [post_date_gmt] => 2021-03-12 13:50:41
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 13:52:46
                            [post_modified_gmt] => 2021-03-12 13:52:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2549
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 2553
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:47:42
                            [post_date_gmt] => 2021-03-12 13:47:42
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 13:49:04
                            [post_modified_gmt] => 2021-03-12 13:49:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2553
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 2554
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:44:47
                            [post_date_gmt] => 2021-03-12 13:44:47
                            [post_content] => 
                            [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-03-12 13:49:36
                            [post_modified_gmt] => 2021-03-12 13:49:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2554
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 2457
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:25:57
                            [post_date_gmt] => 2021-02-25 15:25:57
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:25:57
                            [post_modified_gmt] => 2021-02-25 15:25:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2457
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 2459
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:25:31
                            [post_date_gmt] => 2021-02-25 15:25:31
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:25:31
                            [post_modified_gmt] => 2021-02-25 15:25:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2459
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 2460
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:51
                            [post_date_gmt] => 2021-02-25 15:23:51
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:23:51
                            [post_modified_gmt] => 2021-02-25 15:23:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2460
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 2461
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:35
                            [post_date_gmt] => 2021-02-25 15:23:35
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:23:35
                            [post_modified_gmt] => 2021-02-25 15:23:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2461
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 2462
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:19
                            [post_date_gmt] => 2021-02-25 15:23:19
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:23:19
                            [post_modified_gmt] => 2021-02-25 15:23:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 2463
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:22:52
                            [post_date_gmt] => 2021-02-25 15:22:52
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:22:52
                            [post_modified_gmt] => 2021-02-25 15:22:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2463
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 2464
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:51
                            [post_date_gmt] => 2021-02-25 15:21:51
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:21:51
                            [post_modified_gmt] => 2021-02-25 15:21:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2464
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 2465
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:32
                            [post_date_gmt] => 2021-02-25 15:21:32
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:21:32
                            [post_modified_gmt] => 2021-02-25 15:21:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2465
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 2466
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:40
                            [post_date_gmt] => 2021-02-25 15:20:40
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:20:40
                            [post_modified_gmt] => 2021-02-25 15:20:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2466
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 2467
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:15
                            [post_date_gmt] => 2021-02-25 15:20:15
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:20:15
                            [post_modified_gmt] => 2021-02-25 15:20:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 2470
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:24:13
                            [post_date_gmt] => 2021-01-25 13:24:13
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:24:13
                            [post_modified_gmt] => 2021-01-25 13:24:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2470
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 2472
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:23:03
                            [post_date_gmt] => 2021-01-25 13:23:03
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:23:03
                            [post_modified_gmt] => 2021-01-25 13:23:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2472
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 2473
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:21:58
                            [post_date_gmt] => 2021-01-25 13:21:58
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:21:58
                            [post_modified_gmt] => 2021-01-25 13:21:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2473
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [44] => WP_Post Object
                        (
                            [ID] => 2474
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:19:34
                            [post_date_gmt] => 2021-01-25 13:19:34
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:19:34
                            [post_modified_gmt] => 2021-01-25 13:19:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2474
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [45] => WP_Post Object
                        (
                            [ID] => 2475
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:18:53
                            [post_date_gmt] => 2021-01-25 13:18:53
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:18:53
                            [post_modified_gmt] => 2021-01-25 13:18:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2475
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [46] => WP_Post Object
                        (
                            [ID] => 2476
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:18:09
                            [post_date_gmt] => 2021-01-25 13:18:09
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:18:09
                            [post_modified_gmt] => 2021-01-25 13:18:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2476
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [47] => WP_Post Object
                        (
                            [ID] => 2477
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:16:23
                            [post_date_gmt] => 2021-01-25 13:16:23
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:16:23
                            [post_modified_gmt] => 2021-01-25 13:16:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2477
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [48] => WP_Post Object
                        (
                            [ID] => 2478
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:14:33
                            [post_date_gmt] => 2021-01-25 13:14:33
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:14:33
                            [post_modified_gmt] => 2021-01-25 13:14:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2478
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [49] => WP_Post Object
                        (
                            [ID] => 2479
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:12:32
                            [post_date_gmt] => 2021-01-25 13:12:32
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:12:32
                            [post_modified_gmt] => 2021-01-25 13:12:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2479
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [50] => WP_Post Object
                        (
                            [ID] => 2480
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:11:47
                            [post_date_gmt] => 2021-01-25 13:11:47
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:11:47
                            [post_modified_gmt] => 2021-01-25 13:11:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2480
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [51] => WP_Post Object
                        (
                            [ID] => 2481
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:11:08
                            [post_date_gmt] => 2021-01-25 13:11:08
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:11:08
                            [post_modified_gmt] => 2021-01-25 13:11:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2481
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [52] => WP_Post Object
                        (
                            [ID] => 2482
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:09:37
                            [post_date_gmt] => 2021-01-25 13:09:37
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:09:37
                            [post_modified_gmt] => 2021-01-25 13:09:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [53] => WP_Post Object
                        (
                            [ID] => 2483
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:08:51
                            [post_date_gmt] => 2021-01-25 13:08:51
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:08:51
                            [post_modified_gmt] => 2021-01-25 13:08:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2483
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [54] => WP_Post Object
                        (
                            [ID] => 2471
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:08:02
                            [post_date_gmt] => 2021-01-25 13:08:02
                            [post_content] => 
                            [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:08:02
                            [post_modified_gmt] => 2021-01-25 13:08:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2471
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [55] => WP_Post Object
                        (
                            [ID] => 2454
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:44:16
                            [post_date_gmt] => 2021-01-19 11:44:16
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-19 11:44:16
                            [post_modified_gmt] => 2021-01-19 11:44:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2454
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [56] => WP_Post Object
                        (
                            [ID] => 2452
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:41:19
                            [post_date_gmt] => 2021-01-19 11:41:19
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-19 11:41:19
                            [post_modified_gmt] => 2021-01-19 11:41:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2452
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [57] => WP_Post Object
                        (
                            [ID] => 2450
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:04:23
                            [post_date_gmt] => 2021-01-19 11:04:23
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-19 11:04:23
                            [post_modified_gmt] => 2021-01-19 11:04:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2450
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [58] => WP_Post Object
                        (
                            [ID] => 2449
                            [post_author] => 5
                            [post_date] => 2021-01-19 10:47:27
                            [post_date_gmt] => 2021-01-19 10:47:27
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-19 10:47:27
                            [post_modified_gmt] => 2021-01-19 10:47:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2449
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [59] => WP_Post Object
                        (
                            [ID] => 2448
                            [post_author] => 5
                            [post_date] => 2021-01-19 10:24:45
                            [post_date_gmt] => 2021-01-19 10:24:45
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-19 10:24:45
                            [post_modified_gmt] => 2021-01-19 10:24:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2448
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [60] => WP_Post Object
                        (
                            [ID] => 2445
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:31:14
                            [post_date_gmt] => 2021-01-19 09:31:14
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-19 09:31:14
                            [post_modified_gmt] => 2021-01-19 09:31:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2445
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [61] => WP_Post Object
                        (
                            [ID] => 2444
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:27:20
                            [post_date_gmt] => 2021-01-19 09:27:20
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-19 09:27:20
                            [post_modified_gmt] => 2021-01-19 09:27:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [62] => WP_Post Object
                        (
                            [ID] => 2443
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:14:03
                            [post_date_gmt] => 2021-01-19 09:14:03
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-19 09:14:03
                            [post_modified_gmt] => 2021-01-19 09:14:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2443
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [63] => WP_Post Object
                        (
                            [ID] => 2442
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:56:32
                            [post_date_gmt] => 2021-01-19 06:56:32
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-19 06:56:32
                            [post_modified_gmt] => 2021-01-19 06:56:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2442
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [64] => WP_Post Object
                        (
                            [ID] => 2441
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:48:04
                            [post_date_gmt] => 2021-01-19 06:48:04
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-19 06:48:04
                            [post_modified_gmt] => 2021-01-19 06:48:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2441
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [65] => WP_Post Object
                        (
                            [ID] => 2440
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:45:33
                            [post_date_gmt] => 2021-01-19 06:45:33
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-19 06:45:33
                            [post_modified_gmt] => 2021-01-19 06:45:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2440
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [66] => WP_Post Object
                        (
                            [ID] => 2425
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:02:33
                            [post_date_gmt] => 2020-12-14 15:02:33
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-22 12:13:42
                            [post_modified_gmt] => 2021-01-22 12:13:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2425
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [67] => WP_Post Object
                        (
                            [ID] => 2426
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:02:08
                            [post_date_gmt] => 2020-12-14 15:02:08
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-12-22 13:52:16
                            [post_modified_gmt] => 2020-12-22 13:52:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2426
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [68] => WP_Post Object
                        (
                            [ID] => 2424
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:01:40
                            [post_date_gmt] => 2020-12-14 15:01:40
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-12-22 13:51:02
                            [post_modified_gmt] => 2020-12-22 13:51:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2424
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [69] => WP_Post Object
                        (
                            [ID] => 2422
                            [post_author] => 5
                            [post_date] => 2020-12-14 14:59:29
                            [post_date_gmt] => 2020-12-14 14:59:29
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-25 13:37:01
                            [post_modified_gmt] => 2021-01-25 13:37:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2422
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [70] => WP_Post Object
                        (
                            [ID] => 1395
                            [post_author] => 7
                            [post_date] => 2020-05-30 21:25:33
                            [post_date_gmt] => 2020-05-30 21:25:33
                            [post_content] => 
                            [post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:28:33
                            [post_modified_gmt] => 2020-08-06 08:28:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1395
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [71] => WP_Post Object
                        (
                            [ID] => 1394
                            [post_author] => 7
                            [post_date] => 2020-05-30 21:22:44
                            [post_date_gmt] => 2020-05-30 21:22:44
                            [post_content] => 
                            [post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:40:24
                            [post_modified_gmt] => 2020-08-06 05:40:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1394
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [72] => WP_Post Object
                        (
                            [ID] => 1393
                            [post_author] => 7
                            [post_date] => 2020-05-30 20:13:50
                            [post_date_gmt] => 2020-05-30 20:13:50
                            [post_content] => 
                            [post_title] => Gates Foundation Open Access Policy
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 1393
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 04:49:54
                            [post_modified_gmt] => 2020-08-06 04:49:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1393
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [73] => WP_Post Object
                        (
                            [ID] => 1315
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:56:03
                            [post_date_gmt] => 2020-05-23 17:56:03
                            [post_content] => 
                            [post_title] => MPP License Agreement with ViiV on Dolutegravir for Adults
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-10-10 22:05:56
                            [post_modified_gmt] => 2020-10-10 22:05:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1315
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [74] => WP_Post Object
                        (
                            [ID] => 1313
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:55:00
                            [post_date_gmt] => 2020-05-23 17:55:00
                            [post_content] => 
                            [post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-04 05:11:03
                            [post_modified_gmt] => 2020-08-04 05:11:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1313
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [75] => WP_Post Object
                        (
                            [ID] => 1314
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:54:57
                            [post_date_gmt] => 2020-05-23 17:54:57
                            [post_content] => 
                            [post_title] => MPP Amended and Restated Sublicense and Technology Transfer Agreement under BMS-MPP License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-10-10 22:08:33
                            [post_modified_gmt] => 2020-10-10 22:08:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1314
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [76] => WP_Post Object
                        (
                            [ID] => 1308
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:17:48
                            [post_date_gmt] => 2020-05-23 17:17:48
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 04:59:05
                            [post_modified_gmt] => 2020-08-06 04:59:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1308
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [77] => WP_Post Object
                        (
                            [ID] => 1309
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:17:44
                            [post_date_gmt] => 2020-05-23 17:17:44
                            [post_content] => 
                            [post_title] => IMI 2Joint Undertaking  Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2joint-undertaking-model-consortium-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 04:59:37
                            [post_modified_gmt] => 2020-08-06 04:59:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1309
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [78] => WP_Post Object
                        (
                            [ID] => 1311
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:12:09
                            [post_date_gmt] => 2020-05-23 17:12:09
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:43:06
                            [post_modified_gmt] => 2020-08-06 05:43:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1311
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [79] => WP_Post Object
                        (
                            [ID] => 1310
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:12:02
                            [post_date_gmt] => 2020-05-23 17:12:02
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:30:05
                            [post_modified_gmt] => 2020-08-06 08:30:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1310
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [80] => WP_Post Object
                        (
                            [ID] => 1307
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:05:21
                            [post_date_gmt] => 2020-05-23 17:05:21
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-10-10 22:20:30
                            [post_modified_gmt] => 2020-10-10 22:20:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1307
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [81] => WP_Post Object
                        (
                            [ID] => 1306
                            [post_author] => 7
                            [post_date] => 2020-05-23 16:57:14
                            [post_date_gmt] => 2020-05-23 16:57:14
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:45:45
                            [post_modified_gmt] => 2020-08-06 05:45:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1306
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [82] => WP_Post Object
                        (
                            [ID] => 1305
                            [post_author] => 7
                            [post_date] => 2020-05-23 16:51:40
                            [post_date_gmt] => 2020-05-23 16:51:40
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 1305
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-10-10 22:21:50
                            [post_modified_gmt] => 2020-10-10 22:21:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1305
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [83] => WP_Post Object
                        (
                            [ID] => 1304
                            [post_author] => 7
                            [post_date] => 2020-05-23 16:46:37
                            [post_date_gmt] => 2020-05-23 16:46:37
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:47:49
                            [post_modified_gmt] => 2020-08-06 05:47:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1304
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [84] => WP_Post Object
                        (
                            [ID] => 1303
                            [post_author] => 7
                            [post_date] => 2020-05-23 16:46:30
                            [post_date_gmt] => 2020-05-23 16:46:30
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:48:31
                            [post_modified_gmt] => 2020-08-06 05:48:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1303
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [85] => WP_Post Object
                        (
                            [ID] => 1296
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:46:47
                            [post_date_gmt] => 2020-05-22 23:46:47
                            [post_content] => 
                            [post_title] => WHO
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:49:42
                            [post_modified_gmt] => 2020-08-06 05:49:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1296
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [86] => WP_Post Object
                        (
                            [ID] => 1291
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:42:19
                            [post_date_gmt] => 2020-05-22 23:42:19
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-10-10 22:25:11
                            [post_modified_gmt] => 2020-10-10 22:25:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1291
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [87] => WP_Post Object
                        (
                            [ID] => 1293
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:42:02
                            [post_date_gmt] => 2020-05-22 23:42:02
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:50:33
                            [post_modified_gmt] => 2020-08-06 05:50:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1293
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [88] => WP_Post Object
                        (
                            [ID] => 1288
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:31:30
                            [post_date_gmt] => 2020-05-22 23:31:30
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:15:24
                            [post_modified_gmt] => 2020-08-06 19:15:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1288
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [89] => WP_Post Object
                        (
                            [ID] => 1287
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:05:30
                            [post_date_gmt] => 2020-05-22 23:05:30
                            [post_content] => 
                            [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-07 14:11:07
                            [post_modified_gmt] => 2020-08-07 14:11:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1287
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [90] => WP_Post Object
                        (
                            [ID] => 1285
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:01:07
                            [post_date_gmt] => 2020-05-22 23:01:07
                            [post_content] => 
                            [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:55:08
                            [post_modified_gmt] => 2020-08-06 05:55:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1285
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [91] => WP_Post Object
                        (
                            [ID] => 1284
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:58:55
                            [post_date_gmt] => 2020-05-22 22:58:55
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:55:57
                            [post_modified_gmt] => 2020-08-06 05:55:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1284
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [92] => WP_Post Object
                        (
                            [ID] => 1283
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:57:44
                            [post_date_gmt] => 2020-05-22 22:57:44
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:56:15
                            [post_modified_gmt] => 2020-08-06 05:56:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1283
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [93] => WP_Post Object
                        (
                            [ID] => 1282
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:56:18
                            [post_date_gmt] => 2020-05-22 22:56:18
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:56:57
                            [post_modified_gmt] => 2020-08-06 05:56:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1282
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [94] => WP_Post Object
                        (
                            [ID] => 1281
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:55:22
                            [post_date_gmt] => 2020-05-22 22:55:22
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:57:24
                            [post_modified_gmt] => 2020-08-06 05:57:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1281
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [95] => WP_Post Object
                        (
                            [ID] => 1280
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:54:32
                            [post_date_gmt] => 2020-05-22 22:54:32
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:57:59
                            [post_modified_gmt] => 2020-08-06 05:57:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1280
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [96] => WP_Post Object
                        (
                            [ID] => 1276
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:40:34
                            [post_date_gmt] => 2020-05-22 22:40:34
                            [post_content] => 
                            [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:58:18
                            [post_modified_gmt] => 2020-08-06 05:58:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1276
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [97] => WP_Post Object
                        (
                            [ID] => 1275
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:39:41
                            [post_date_gmt] => 2020-05-22 22:39:41
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:58:40
                            [post_modified_gmt] => 2020-08-06 05:58:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1275
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [98] => WP_Post Object
                        (
                            [ID] => 1274
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:38:47
                            [post_date_gmt] => 2020-05-22 22:38:47
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:59:08
                            [post_modified_gmt] => 2020-08-06 05:59:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1274
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [99] => WP_Post Object
                        (
                            [ID] => 1273
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:37:54
                            [post_date_gmt] => 2020-05-22 22:37:54
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-04 04:20:47
                            [post_modified_gmt] => 2020-08-04 04:20:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1273
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [100] => WP_Post Object
                        (
                            [ID] => 1272
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:36:39
                            [post_date_gmt] => 2020-05-22 22:36:39
                            [post_content] => 
                            [post_title] => BU Startup Exclusive License
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bu-startup-exclusive-license-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:59:41
                            [post_modified_gmt] => 2020-08-06 05:59:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1272
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [101] => WP_Post Object
                        (
                            [ID] => 1271
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:34:12
                            [post_date_gmt] => 2020-05-22 22:34:12
                            [post_content] => 
                            [post_title] => WHO Standard Framework Memorandum of Understanding
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-standard-framework-memorandum-of-understanding-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:00:10
                            [post_modified_gmt] => 2020-08-06 06:00:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1271
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [102] => WP_Post Object
                        (
                            [ID] => 1270
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:32:29
                            [post_date_gmt] => 2020-05-22 22:32:29
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-10-18 11:46:22
                            [post_modified_gmt] => 2020-10-18 11:46:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1270
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [103] => WP_Post Object
                        (
                            [ID] => 1269
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:29:54
                            [post_date_gmt] => 2020-05-22 22:29:54
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:01:05
                            [post_modified_gmt] => 2020-08-06 06:01:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1269
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [104] => WP_Post Object
                        (
                            [ID] => 1268
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:27:54
                            [post_date_gmt] => 2020-05-22 22:27:54
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:01:30
                            [post_modified_gmt] => 2020-08-06 06:01:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1268
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [105] => WP_Post Object
                        (
                            [ID] => 1267
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:26:39
                            [post_date_gmt] => 2020-05-22 22:26:39
                            [post_content] => 
                            [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:02:22
                            [post_modified_gmt] => 2020-08-06 06:02:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1267
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [106] => WP_Post Object
                        (
                            [ID] => 1266
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:25:16
                            [post_date_gmt] => 2020-05-22 22:25:16
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:03:25
                            [post_modified_gmt] => 2020-08-06 06:03:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1266
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [107] => WP_Post Object
                        (
                            [ID] => 1265
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:24:11
                            [post_date_gmt] => 2020-05-22 22:24:11
                            [post_content] => 
                            [post_title] => WHO Template Material Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-template-material-transfer-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:03:50
                            [post_modified_gmt] => 2020-08-06 06:03:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1265
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [108] => WP_Post Object
                        (
                            [ID] => 1264
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:22:55
                            [post_date_gmt] => 2020-05-22 22:22:55
                            [post_content] => 
                            [post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:04:26
                            [post_modified_gmt] => 2020-08-06 06:04:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1264
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [109] => WP_Post Object
                        (
                            [ID] => 1263
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:20:56
                            [post_date_gmt] => 2020-05-22 22:20:56
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:21:52
                            [post_modified_gmt] => 2020-08-06 19:21:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1263
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [110] => WP_Post Object
                        (
                            [ID] => 1262
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:18:41
                            [post_date_gmt] => 2020-05-22 22:18:41
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:05:46
                            [post_modified_gmt] => 2020-08-06 06:05:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1262
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [111] => WP_Post Object
                        (
                            [ID] => 1261
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:17:34
                            [post_date_gmt] => 2020-05-22 22:17:34
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:06:36
                            [post_modified_gmt] => 2020-08-06 06:06:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1261
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [112] => WP_Post Object
                        (
                            [ID] => 1259
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:04:31
                            [post_date_gmt] => 2020-05-22 22:04:31
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:06:50
                            [post_modified_gmt] => 2020-08-06 06:06:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1259
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [113] => WP_Post Object
                        (
                            [ID] => 1258
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:03:08
                            [post_date_gmt] => 2020-05-22 22:03:08
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:07:40
                            [post_modified_gmt] => 2020-08-06 06:07:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1258
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [114] => WP_Post Object
                        (
                            [ID] => 1257
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:54:08
                            [post_date_gmt] => 2020-05-22 21:54:08
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:08:19
                            [post_modified_gmt] => 2020-08-06 06:08:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1257
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [115] => WP_Post Object
                        (
                            [ID] => 1255
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:49:26
                            [post_date_gmt] => 2020-05-22 21:49:26
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:09:08
                            [post_modified_gmt] => 2020-08-06 06:09:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1255
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [116] => WP_Post Object
                        (
                            [ID] => 1254
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:44:49
                            [post_date_gmt] => 2020-05-22 21:44:49
                            [post_content] => 
                            [post_title] => Gates Foundation Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-data-materials-sharing-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:09:56
                            [post_modified_gmt] => 2020-08-06 06:09:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1254
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [117] => WP_Post Object
                        (
                            [ID] => 1253
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:42:28
                            [post_date_gmt] => 2020-05-22 21:42:28
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:38:41
                            [post_modified_gmt] => 2020-08-06 19:38:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1253
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [118] => WP_Post Object
                        (
                            [ID] => 1252
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:41:17
                            [post_date_gmt] => 2020-05-22 21:41:17
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:25:32
                            [post_modified_gmt] => 2020-08-06 06:25:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1252
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [119] => WP_Post Object
                        (
                            [ID] => 1251
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:39:48
                            [post_date_gmt] => 2020-05-22 21:39:48
                            [post_content] => 
                            [post_title] => CAVD Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cavd-data-materials-sharing-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:40:50
                            [post_modified_gmt] => 2020-08-06 19:40:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1251
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [120] => WP_Post Object
                        (
                            [ID] => 1250
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:38:31
                            [post_date_gmt] => 2020-05-22 21:38:31
                            [post_content] => 
                            [post_title] => CAVD Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cavd-data-materials-sharing-agreement-2-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:41:55
                            [post_modified_gmt] => 2020-08-06 19:41:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1250
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [121] => WP_Post Object
                        (
                            [ID] => 1249
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:37:42
                            [post_date_gmt] => 2020-05-22 21:37:42
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:22:26
                            [post_modified_gmt] => 2020-08-06 06:22:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1249
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [122] => WP_Post Object
                        (
                            [ID] => 1248
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:36:47
                            [post_date_gmt] => 2020-05-22 21:36:47
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:19:18
                            [post_modified_gmt] => 2020-08-06 06:19:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1248
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [123] => WP_Post Object
                        (
                            [ID] => 1247
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:33:54
                            [post_date_gmt] => 2020-05-22 21:33:54
                            [post_content] => 
                            [post_title] => WHO Mutual Confidential Disclosure Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-mutual-confidential-disclosure-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:18:47
                            [post_modified_gmt] => 2020-08-06 06:18:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1247
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [124] => WP_Post Object
                        (
                            [ID] => 1245
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:32:14
                            [post_date_gmt] => 2020-05-22 21:32:14
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:17:49
                            [post_modified_gmt] => 2020-08-06 06:17:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1245
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [125] => WP_Post Object
                        (
                            [ID] => 1244
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:30:57
                            [post_date_gmt] => 2020-05-22 21:30:57
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:16:51
                            [post_modified_gmt] => 2020-08-06 06:16:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1244
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [126] => WP_Post Object
                        (
                            [ID] => 1243
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:29:10
                            [post_date_gmt] => 2020-05-22 21:29:10
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:15:56
                            [post_modified_gmt] => 2020-08-06 06:15:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1243
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [127] => WP_Post Object
                        (
                            [ID] => 1242
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:26:04
                            [post_date_gmt] => 2020-05-22 21:26:04
                            [post_content] => 
                            [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:45:06
                            [post_modified_gmt] => 2020-08-06 19:45:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1242
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [128] => WP_Post Object
                        (
                            [ID] => 1241
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:24:25
                            [post_date_gmt] => 2020-05-22 21:24:25
                            [post_content] => 
                            [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:13:20
                            [post_modified_gmt] => 2020-08-06 06:13:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1241
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [129] => WP_Post Object
                        (
                            [ID] => 1240
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:22:47
                            [post_date_gmt] => 2020-05-22 21:22:47
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:11:52
                            [post_modified_gmt] => 2020-08-06 06:11:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1240
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [130] => WP_Post Object
                        (
                            [ID] => 1239
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:21:49
                            [post_date_gmt] => 2020-05-22 21:21:49
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:27:18
                            [post_modified_gmt] => 2020-08-06 06:27:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1239
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [131] => WP_Post Object
                        (
                            [ID] => 1238
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:20:51
                            [post_date_gmt] => 2020-05-22 21:20:51
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:29:07
                            [post_modified_gmt] => 2020-08-06 06:29:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1238
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [132] => WP_Post Object
                        (
                            [ID] => 1237
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:19:08
                            [post_date_gmt] => 2020-05-22 21:19:08
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:29:51
                            [post_modified_gmt] => 2020-08-06 06:29:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1237
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [133] => WP_Post Object
                        (
                            [ID] => 1236
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:17:57
                            [post_date_gmt] => 2020-05-22 21:17:57
                            [post_content] => 
                            [post_title] => WHO Template Material Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-template-material-transfer-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:30:25
                            [post_modified_gmt] => 2020-08-06 06:30:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1236
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [134] => WP_Post Object
                        (
                            [ID] => 1235
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:01:14
                            [post_date_gmt] => 2020-05-22 21:01:14
                            [post_content] => 
                            [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:33:13
                            [post_modified_gmt] => 2020-08-06 06:33:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1235
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [135] => WP_Post Object
                        (
                            [ID] => 1233
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:00:08
                            [post_date_gmt] => 2020-05-22 21:00:08
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:49:06
                            [post_modified_gmt] => 2020-08-06 19:49:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1233
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [136] => WP_Post Object
                        (
                            [ID] => 1232
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:57:46
                            [post_date_gmt] => 2020-05-22 20:57:46
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:35:49
                            [post_modified_gmt] => 2020-08-06 06:35:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1232
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [137] => WP_Post Object
                        (
                            [ID] => 1231
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:54:50
                            [post_date_gmt] => 2020-05-22 20:54:50
                            [post_content] => 
                            [post_title] => CAVD Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cavd-data-materials-sharing-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:37:41
                            [post_modified_gmt] => 2020-08-06 06:37:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1231
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [138] => WP_Post Object
                        (
                            [ID] => 1229
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:51:35
                            [post_date_gmt] => 2020-05-22 20:51:35
                            [post_content] => 
                            [post_title] => MPP License Agreement with BMS & Aurobindo Pharma Ltd.
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:39:20
                            [post_modified_gmt] => 2020-08-06 06:39:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1229
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [139] => WP_Post Object
                        (
                            [ID] => 1228
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:49:20
                            [post_date_gmt] => 2020-05-22 20:49:20
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:52:03
                            [post_modified_gmt] => 2020-08-06 19:52:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1228
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [140] => WP_Post Object
                        (
                            [ID] => 1227
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:48:27
                            [post_date_gmt] => 2020-05-22 20:48:27
                            [post_content] => 
                            [post_title] => Ebola WHO-Manufacturer LOA (Annex)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ebola-who-manufacturer-loa-annex
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:52:47
                            [post_modified_gmt] => 2020-08-06 19:52:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1227
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [141] => WP_Post Object
                        (
                            [ID] => 1226
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:47:05
                            [post_date_gmt] => 2020-05-22 20:47:05
                            [post_content] => 
                            [post_title] => WHO Template Material Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-template-material-transfer-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:44:21
                            [post_modified_gmt] => 2020-08-06 06:44:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1226
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [142] => WP_Post Object
                        (
                            [ID] => 1225
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:43:20
                            [post_date_gmt] => 2020-05-22 20:43:20
                            [post_content] => 
                            [post_title] => WHO Template Material Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-template-material-transfer-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:45:39
                            [post_modified_gmt] => 2020-08-06 06:45:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1225
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [143] => WP_Post Object
                        (
                            [ID] => 1223
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:14:40
                            [post_date_gmt] => 2020-05-22 20:14:40
                            [post_content] => 
                            [post_title] => Ten Principles for Socially Responsible Licensing, by Netherlands Federation of University Medical Centers (June 2019)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:46:21
                            [post_modified_gmt] => 2020-08-06 06:46:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1223
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [144] => WP_Post Object
                        (
                            [ID] => 1222
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:12:04
                            [post_date_gmt] => 2020-05-22 20:12:04
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfpi3-template-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:47:07
                            [post_modified_gmt] => 2020-08-06 06:47:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1222
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [145] => WP_Post Object
                        (
                            [ID] => 1221
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:09:53
                            [post_date_gmt] => 2020-05-22 20:09:53
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfpi3-template-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:55:03
                            [post_modified_gmt] => 2020-08-06 19:55:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [146] => WP_Post Object
                        (
                            [ID] => 1220
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:05:59
                            [post_date_gmt] => 2020-05-22 20:05:59
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:48:16
                            [post_modified_gmt] => 2020-08-06 06:48:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1220
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [147] => WP_Post Object
                        (
                            [ID] => 1218
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:04:53
                            [post_date_gmt] => 2020-05-22 20:04:53
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:57:30
                            [post_modified_gmt] => 2020-08-06 19:57:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1218
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [148] => WP_Post Object
                        (
                            [ID] => 1217
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:00:26
                            [post_date_gmt] => 2020-05-22 20:00:26
                            [post_content] => 
                            [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => edctp2-policy-on-clinical-trials-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:16:02
                            [post_modified_gmt] => 2020-08-06 07:16:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1217
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [149] => WP_Post Object
                        (
                            [ID] => 1216
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:58:08
                            [post_date_gmt] => 2020-05-22 19:58:08
                            [post_content] => 
                            [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => edctp2-policy-on-clinical-trials
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:54:51
                            [post_modified_gmt] => 2020-08-06 06:54:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1216
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [150] => WP_Post Object
                        (
                            [ID] => 1215
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:56:47
                            [post_date_gmt] => 2020-05-22 19:56:47
                            [post_content] => 
                            [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => edctp2-policy-on-clinical-trials-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:56:31
                            [post_modified_gmt] => 2020-08-06 06:56:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1215
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [151] => WP_Post Object
                        (
                            [ID] => 1214
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:55:41
                            [post_date_gmt] => 2020-05-22 19:55:41
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:57:53
                            [post_modified_gmt] => 2020-08-06 06:57:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1214
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [152] => WP_Post Object
                        (
                            [ID] => 1211
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:50:22
                            [post_date_gmt] => 2020-05-22 19:50:22
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:58:52
                            [post_modified_gmt] => 2020-08-06 06:58:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1211
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [153] => WP_Post Object
                        (
                            [ID] => 1210
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:49:19
                            [post_date_gmt] => 2020-05-22 19:49:19
                            [post_content] => 
                            [post_title] => Ten Principles for Socially Responsible Licensing, by Netherlands Federation of University Medical Centers (June 2019)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:59:22
                            [post_modified_gmt] => 2020-08-06 06:59:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1210
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [154] => WP_Post Object
                        (
                            [ID] => 1207
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:42:36
                            [post_date_gmt] => 2020-05-22 19:42:36
                            [post_content] => 
                            [post_title] => MPP License Agreement with Pfizer re Sutezolid
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-pfizer-re-sutezolid
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:59:52
                            [post_modified_gmt] => 2020-08-06 06:59:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1207
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [155] => WP_Post Object
                        (
                            [ID] => 1206
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:37:27
                            [post_date_gmt] => 2020-05-22 19:37:27
                            [post_content] => 
                            [post_title] => Gates Global Access Commitment & Humanitarian License
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-global-access-commitment-and-humanitarian-license
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:00:51
                            [post_modified_gmt] => 2020-08-06 07:00:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [156] => WP_Post Object
                        (
                            [ID] => 1200
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:35:05
                            [post_date_gmt] => 2020-05-22 19:35:05
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 20:02:26
                            [post_modified_gmt] => 2020-08-06 20:02:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1200
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [157] => WP_Post Object
                        (
                            [ID] => 1205
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:33:17
                            [post_date_gmt] => 2020-05-22 19:33:17
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:04:45
                            [post_modified_gmt] => 2020-08-06 07:04:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [158] => WP_Post Object
                        (
                            [ID] => 1204
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:31:46
                            [post_date_gmt] => 2020-05-22 19:31:46
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:06:42
                            [post_modified_gmt] => 2020-08-06 07:06:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [159] => WP_Post Object
                        (
                            [ID] => 1203
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:30:52
                            [post_date_gmt] => 2020-05-22 19:30:52
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:07:29
                            [post_modified_gmt] => 2020-08-06 07:07:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [160] => WP_Post Object
                        (
                            [ID] => 1202
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:28:49
                            [post_date_gmt] => 2020-05-22 19:28:49
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-09-06 23:38:12
                            [post_modified_gmt] => 2020-09-06 23:38:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [161] => WP_Post Object
                        (
                            [ID] => 1201
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:26:29
                            [post_date_gmt] => 2020-05-22 19:26:29
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:09:26
                            [post_modified_gmt] => 2020-08-06 07:09:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1201
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [162] => WP_Post Object
                        (
                            [ID] => 1199
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:21:57
                            [post_date_gmt] => 2020-05-22 19:21:57
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:11:10
                            [post_modified_gmt] => 2020-08-06 07:11:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1199
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [163] => WP_Post Object
                        (
                            [ID] => 1198
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:12:54
                            [post_date_gmt] => 2020-05-22 19:12:54
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:12:41
                            [post_modified_gmt] => 2020-08-06 07:12:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1198
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [164] => WP_Post Object
                        (
                            [ID] => 1193
                            [post_author] => 6
                            [post_date] => 2020-05-22 02:10:10
                            [post_date_gmt] => 2020-05-22 02:10:10
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-04 04:18:05
                            [post_modified_gmt] => 2020-08-04 04:18:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1193
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [165] => WP_Post Object
                        (
                            [ID] => 1190
                            [post_author] => 6
                            [post_date] => 2020-05-22 01:59:48
                            [post_date_gmt] => 2020-05-22 01:59:48
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:13:53
                            [post_modified_gmt] => 2020-08-06 07:13:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1190
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [166] => WP_Post Object
                        (
                            [ID] => 1187
                            [post_author] => 6
                            [post_date] => 2020-05-22 01:56:10
                            [post_date_gmt] => 2020-05-22 01:56:10
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:15:18
                            [post_modified_gmt] => 2020-08-06 07:15:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1187
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [167] => WP_Post Object
                        (
                            [ID] => 1186
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:11:20
                            [post_date_gmt] => 2020-05-22 00:11:20
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:19:26
                            [post_modified_gmt] => 2020-08-06 07:19:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1186
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [168] => WP_Post Object
                        (
                            [ID] => 1185
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:10:01
                            [post_date_gmt] => 2020-05-22 00:10:01
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:19:08
                            [post_modified_gmt] => 2020-08-06 07:19:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1185
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [169] => WP_Post Object
                        (
                            [ID] => 1184
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:08:17
                            [post_date_gmt] => 2020-05-22 00:08:17
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-12 17:41:36
                            [post_modified_gmt] => 2021-04-12 17:41:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1184
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [170] => WP_Post Object
                        (
                            [ID] => 1183
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:06:26
                            [post_date_gmt] => 2020-05-22 00:06:26
                            [post_content] => 
                            [post_title] => MPP License Agreement with AbbVie (LPV r)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-abbvie
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:20:18
                            [post_modified_gmt] => 2020-08-06 07:20:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1183
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [171] => WP_Post Object
                        (
                            [ID] => 1182
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:02:42
                            [post_date_gmt] => 2020-05-22 00:02:42
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 20:22:28
                            [post_modified_gmt] => 2020-08-06 20:22:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1182
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [172] => WP_Post Object
                        (
                            [ID] => 1179
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:58:21
                            [post_date_gmt] => 2020-05-21 23:58:21
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 20:23:03
                            [post_modified_gmt] => 2020-08-06 20:23:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1179
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [173] => WP_Post Object
                        (
                            [ID] => 1178
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:55:50
                            [post_date_gmt] => 2020-05-21 23:55:50
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:23:22
                            [post_modified_gmt] => 2020-08-06 07:23:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1178
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [174] => WP_Post Object
                        (
                            [ID] => 1177
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:53:56
                            [post_date_gmt] => 2020-05-21 23:53:56
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:24:45
                            [post_modified_gmt] => 2020-08-06 07:24:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1177
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [175] => WP_Post Object
                        (
                            [ID] => 1176
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:52:12
                            [post_date_gmt] => 2020-05-21 23:52:12
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:26:01
                            [post_modified_gmt] => 2020-08-06 07:26:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1176
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [176] => WP_Post Object
                        (
                            [ID] => 1175
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:44:57
                            [post_date_gmt] => 2020-05-21 23:44:57
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:28:09
                            [post_modified_gmt] => 2020-08-06 07:28:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1175
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [177] => WP_Post Object
                        (
                            [ID] => 1173
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:37:42
                            [post_date_gmt] => 2020-05-21 23:37:42
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 20:28:01
                            [post_modified_gmt] => 2020-08-06 20:28:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1173
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [178] => WP_Post Object
                        (
                            [ID] => 1172
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:35:57
                            [post_date_gmt] => 2020-05-21 23:35:57
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:48:07
                            [post_modified_gmt] => 2020-08-06 07:48:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1172
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [179] => WP_Post Object
                        (
                            [ID] => 1171
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:33:24
                            [post_date_gmt] => 2020-05-21 23:33:24
                            [post_content] => 
                            [post_title] => IMI 1 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-1-model-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:34:16
                            [post_modified_gmt] => 2020-08-06 07:34:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1171
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [180] => WP_Post Object
                        (
                            [ID] => 1170
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:28:59
                            [post_date_gmt] => 2020-05-21 23:28:59
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:46:46
                            [post_modified_gmt] => 2020-08-06 07:46:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1170
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [181] => WP_Post Object
                        (
                            [ID] => 1168
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:26:48
                            [post_date_gmt] => 2020-05-21 23:26:48
                            [post_content] => 
                            [post_title] => NIH Model License Agreement for Use by Non-Profit
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-model-license-agreement-for-use-by-non-profit-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:45:59
                            [post_modified_gmt] => 2020-08-06 07:45:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1168
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [182] => WP_Post Object
                        (
                            [ID] => 1166
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:26:07
                            [post_date_gmt] => 2020-05-21 23:26:07
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:45:40
                            [post_modified_gmt] => 2020-08-06 07:45:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1166
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [183] => WP_Post Object
                        (
                            [ID] => 1165
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:23:57
                            [post_date_gmt] => 2020-05-21 23:23:57
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:44:57
                            [post_modified_gmt] => 2020-08-06 07:44:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1165
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [184] => WP_Post Object
                        (
                            [ID] => 1164
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:22:37
                            [post_date_gmt] => 2020-05-21 23:22:37
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 20:30:07
                            [post_modified_gmt] => 2020-08-06 20:30:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1164
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [185] => WP_Post Object
                        (
                            [ID] => 1162
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:19:43
                            [post_date_gmt] => 2020-05-21 23:19:43
                            [post_content] => 
                            [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:43:25
                            [post_modified_gmt] => 2020-08-06 07:43:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1162
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [186] => WP_Post Object
                        (
                            [ID] => 1160
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:18:03
                            [post_date_gmt] => 2020-05-21 23:18:03
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:41:09
                            [post_modified_gmt] => 2020-08-06 07:41:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1160
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [187] => WP_Post Object
                        (
                            [ID] => 1159
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:14:15
                            [post_date_gmt] => 2020-05-21 23:14:15
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:39:58
                            [post_modified_gmt] => 2020-08-06 07:39:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [188] => WP_Post Object
                        (
                            [ID] => 1158
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:12:13
                            [post_date_gmt] => 2020-05-21 23:12:13
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:38:32
                            [post_modified_gmt] => 2020-08-06 07:38:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1158
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [189] => WP_Post Object
                        (
                            [ID] => 1156
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:10:39
                            [post_date_gmt] => 2020-05-21 23:10:39
                            [post_content] => 
                            [post_title] => WHO Standard Framework Memorandum of Understanding
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-standard-framework-memorandum-of-understanding
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:36:26
                            [post_modified_gmt] => 2020-08-06 07:36:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1156
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [190] => WP_Post Object
                        (
                            [ID] => 1155
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:09:39
                            [post_date_gmt] => 2020-05-21 23:09:39
                            [post_content] => 
                            [post_title] => WHO Template Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => template-collaboration-agreement-with-who
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:13:07
                            [post_modified_gmt] => 2020-08-06 08:13:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1155
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [191] => WP_Post Object
                        (
                            [ID] => 1150
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:53:25
                            [post_date_gmt] => 2020-05-21 22:53:25
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:15:03
                            [post_modified_gmt] => 2020-08-06 08:15:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [192] => WP_Post Object
                        (
                            [ID] => 1147
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:50:33
                            [post_date_gmt] => 2020-05-21 22:50:33
                            [post_content] => 
                            [post_title] => IMI 1 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-1-model-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:15:52
                            [post_modified_gmt] => 2020-08-06 08:15:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1147
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [193] => WP_Post Object
                        (
                            [ID] => 1145
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:48:08
                            [post_date_gmt] => 2020-05-21 22:48:08
                            [post_content] => 
                            [post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:17:09
                            [post_modified_gmt] => 2020-08-06 08:17:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1145
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [194] => WP_Post Object
                        (
                            [ID] => 1143
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:46:30
                            [post_date_gmt] => 2020-05-21 22:46:30
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:18:12
                            [post_modified_gmt] => 2020-08-06 08:18:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1143
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [195] => WP_Post Object
                        (
                            [ID] => 1141
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:43:46
                            [post_date_gmt] => 2020-05-21 22:43:46
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:19:21
                            [post_modified_gmt] => 2020-08-06 08:19:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1141
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [196] => WP_Post Object
                        (
                            [ID] => 1140
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:37:27
                            [post_date_gmt] => 2020-05-21 22:37:27
                            [post_content] => 
                            [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:21:40
                            [post_modified_gmt] => 2020-08-06 08:21:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1140
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [197] => WP_Post Object
                        (
                            [ID] => 1139
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:35:04
                            [post_date_gmt] => 2020-05-21 22:35:04
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:22:26
                            [post_modified_gmt] => 2020-08-06 08:22:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1139
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [198] => WP_Post Object
                        (
                            [ID] => 1137
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:22:50
                            [post_date_gmt] => 2020-05-21 22:22:50
                            [post_content] => 
                            [post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:25:03
                            [post_modified_gmt] => 2020-08-06 08:25:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1137
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [199] => WP_Post Object
                        (
                            [ID] => 1135
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:19:46
                            [post_date_gmt] => 2020-05-21 22:19:46
                            [post_content] => 
                            [post_title] => NIH Model License Agreement for Use by Non-Profit
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-model-license-agreement-for-use-by-non-profit
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:25:31
                            [post_modified_gmt] => 2020-08-06 08:25:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1135
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [200] => WP_Post Object
                        (
                            [ID] => 1134
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:00:36
                            [post_date_gmt] => 2020-05-21 22:00:36
                            [post_content] => 
                            [post_title] => CAVD Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cavd-data-materials-sharing-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:25:48
                            [post_modified_gmt] => 2020-08-06 08:25:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1134
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [201] => WP_Post Object
                        (
                            [ID] => 1132
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:58:10
                            [post_date_gmt] => 2020-05-21 21:58:10
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-12 15:04:08
                            [post_modified_gmt] => 2021-04-12 15:04:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1132
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [202] => WP_Post Object
                        (
                            [ID] => 1131
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:56:27
                            [post_date_gmt] => 2020-05-21 21:56:27
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-%c2%a725-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:12:00
                            [post_modified_gmt] => 2020-08-06 08:12:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1131
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [203] => WP_Post Object
                        (
                            [ID] => 1129
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:51:51
                            [post_date_gmt] => 2020-05-21 21:51:51
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement §25.2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:10:01
                            [post_modified_gmt] => 2020-08-06 08:10:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1129
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [204] => WP_Post Object
                        (
                            [ID] => 1128
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:50:04
                            [post_date_gmt] => 2020-05-21 21:50:04
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:09:28
                            [post_modified_gmt] => 2020-08-06 08:09:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1128
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [205] => WP_Post Object
                        (
                            [ID] => 1127
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:47:49
                            [post_date_gmt] => 2020-05-21 21:47:49
                            [post_content] => 
                            [post_title] => BU Startup Exclusive License
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bu-startup-exclusive-license
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:08:46
                            [post_modified_gmt] => 2020-08-06 08:08:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1127
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [206] => WP_Post Object
                        (
                            [ID] => 1125
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:44:59
                            [post_date_gmt] => 2020-05-21 21:44:59
                            [post_content] => 
                            [post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:08:05
                            [post_modified_gmt] => 2020-08-06 08:08:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1125
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [207] => WP_Post Object
                        (
                            [ID] => 1124
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:41:21
                            [post_date_gmt] => 2020-05-21 21:41:21
                            [post_content] => 
                            [post_title] => MPP Amended and Restated Sublicense and Technology Transfer Agreement under BMS-MPP License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-12 14:55:27
                            [post_modified_gmt] => 2021-04-12 14:55:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1124
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [208] => WP_Post Object
                        (
                            [ID] => 1123
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:37:52
                            [post_date_gmt] => 2020-05-21 21:37:52
                            [post_content] => 
                            [post_title] => MPP License Agreement with ViiV on Dolutegravir for Adults
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:02:41
                            [post_modified_gmt] => 2020-08-06 08:02:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [209] => WP_Post Object
                        (
                            [ID] => 1122
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:30:19
                            [post_date_gmt] => 2020-05-21 21:30:19
                            [post_content] => 
                            [post_title] => MPP License Agreement with BMS & Aurobindo Pharma Ltd.
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:02:05
                            [post_modified_gmt] => 2020-08-06 08:02:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1122
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [210] => WP_Post Object
                        (
                            [ID] => 1120
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:28:37
                            [post_date_gmt] => 2020-05-21 21:28:37
                            [post_content] => 
                            [post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:00:43
                            [post_modified_gmt] => 2020-08-06 08:00:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1120
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [211] => WP_Post Object
                        (
                            [ID] => 1118
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:24:00
                            [post_date_gmt] => 2020-05-21 21:24:00
                            [post_content] => 
                            [post_title] => MPP License Agreement with AbbVie (LPV r)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpps-license-agreement-with-abbvie
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:59:29
                            [post_modified_gmt] => 2020-08-06 07:59:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1118
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [212] => WP_Post Object
                        (
                            [ID] => 1117
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:17:31
                            [post_date_gmt] => 2020-05-21 21:17:31
                            [post_content] => 
                            [post_title] => MPP License Agreement with University of Liverpool
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpps-license-agreement-with-university-of-liverpool
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:58:09
                            [post_modified_gmt] => 2020-08-06 07:58:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1117
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [213] => WP_Post Object
                        (
                            [ID] => 1114
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:13:15
                            [post_date_gmt] => 2020-05-21 21:13:15
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:55:36
                            [post_modified_gmt] => 2020-08-06 07:55:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1114
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [214] => WP_Post Object
                        (
                            [ID] => 1113
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:09:47
                            [post_date_gmt] => 2020-05-21 21:09:47
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:54:21
                            [post_modified_gmt] => 2020-08-06 07:54:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1113
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [215] => WP_Post Object
                        (
                            [ID] => 1112
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:06:05
                            [post_date_gmt] => 2020-05-21 21:06:05
                            [post_content] => 
                            [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:53:41
                            [post_modified_gmt] => 2020-08-06 07:53:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1112
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [216] => WP_Post Object
                        (
                            [ID] => 1111
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:03:23
                            [post_date_gmt] => 2020-05-21 21:03:23
                            [post_content] => 
                            [post_title] => IMI 1 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-1-model-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:53:03
                            [post_modified_gmt] => 2020-08-06 07:53:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1111
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [217] => WP_Post Object
                        (
                            [ID] => 1109
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:01:18
                            [post_date_gmt] => 2020-05-21 21:01:18
                            [post_content] => 
                            [post_title] => CAVD Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cavd-data-materials-sharing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-04 04:28:44
                            [post_modified_gmt] => 2020-08-04 04:28:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1109
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [218] => WP_Post Object
                        (
                            [ID] => 1108
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:59:47
                            [post_date_gmt] => 2020-05-21 20:59:47
                            [post_content] => 
                            [post_title] => WHO Template Material Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-template-material-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:51:26
                            [post_modified_gmt] => 2020-08-06 07:51:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1108
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [219] => WP_Post Object
                        (
                            [ID] => 1107
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:57:25
                            [post_date_gmt] => 2020-05-21 20:57:25
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:50:28
                            [post_modified_gmt] => 2020-08-06 07:50:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1107
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [220] => WP_Post Object
                        (
                            [ID] => 996
                            [post_author] => 7
                            [post_date] => 2020-05-18 19:58:18
                            [post_date_gmt] => 2020-05-18 19:58:18
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:49:31
                            [post_modified_gmt] => 2020-08-06 07:49:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 221
            [current_post] => -1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 2824
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:39:49
                    [post_date_gmt] => 2021-04-16 16:39:49
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 16:39:49
                    [post_modified_gmt] => 2021-04-16 16:39:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2824
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 221
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => 1c3df41be9f14460b814a5bb3f65f565
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [stopwords:WP_Query:private] => 
            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [text_agreement_q_rslts] => 
    [text_provision_q_rslts] => 
    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 2824
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:39:49
                    [post_date_gmt] => 2021-04-16 16:39:49
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 16:39:49
                    [post_modified_gmt] => 2021-04-16 16:39:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2824
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 2823
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:17:11
                    [post_date_gmt] => 2021-04-16 16:17:11
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 16:17:11
                    [post_modified_gmt] => 2021-04-16 16:17:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2823
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 2822
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:09:31
                    [post_date_gmt] => 2021-04-16 16:09:31
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 16:09:31
                    [post_modified_gmt] => 2021-04-16 16:09:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2822
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 2821
                    [post_author] => 5
                    [post_date] => 2021-04-16 12:55:04
                    [post_date_gmt] => 2021-04-16 12:55:04
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 12:55:04
                    [post_modified_gmt] => 2021-04-16 12:55:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2821
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 2820
                    [post_author] => 5
                    [post_date] => 2021-04-16 12:44:14
                    [post_date_gmt] => 2021-04-16 12:44:14
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 12:44:14
                    [post_modified_gmt] => 2021-04-16 12:44:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2820
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 2819
                    [post_author] => 5
                    [post_date] => 2021-04-16 12:12:32
                    [post_date_gmt] => 2021-04-16 12:12:32
                    [post_content] => 
                    [post_title] => Regeneron - ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 12:15:57
                    [post_modified_gmt] => 2021-04-16 12:15:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2819
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 2744
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:12:35
                    [post_date_gmt] => 2021-03-30 15:12:35
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-30 15:12:35
                    [post_modified_gmt] => 2021-03-30 15:12:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 2749
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:10:16
                    [post_date_gmt] => 2021-03-30 15:10:16
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-30 15:10:16
                    [post_modified_gmt] => 2021-03-30 15:10:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2749
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 2748
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:05:46
                    [post_date_gmt] => 2021-03-30 15:05:46
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 2748
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-30 15:06:12
                    [post_modified_gmt] => 2021-03-30 15:06:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2748
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 2740
                    [post_author] => 5
                    [post_date] => 2021-03-30 14:54:54
                    [post_date_gmt] => 2021-03-30 14:54:54
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-30 14:54:54
                    [post_modified_gmt] => 2021-03-30 14:54:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2740
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 2743
                    [post_author] => 5
                    [post_date] => 2021-03-24 15:11:40
                    [post_date_gmt] => 2021-03-24 15:11:40
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-24 15:11:40
                    [post_modified_gmt] => 2021-03-24 15:11:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2743
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 2742
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:37:07
                    [post_date_gmt] => 2021-03-24 13:37:07
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-24 13:37:07
                    [post_modified_gmt] => 2021-03-24 13:37:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2742
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 2741
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:32:55
                    [post_date_gmt] => 2021-03-24 13:32:55
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-24 13:32:55
                    [post_modified_gmt] => 2021-03-24 13:32:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2741
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 2739
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:12:14
                    [post_date_gmt] => 2021-03-24 13:12:14
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-24 13:12:14
                    [post_modified_gmt] => 2021-03-24 13:12:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2739
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 2738
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:04:24
                    [post_date_gmt] => 2021-03-24 13:04:24
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-24 13:04:24
                    [post_modified_gmt] => 2021-03-24 13:04:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2738
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [15] => WP_Post Object
                (
                    [ID] => 2737
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:00:46
                    [post_date_gmt] => 2021-03-24 13:00:46
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-24 13:00:46
                    [post_modified_gmt] => 2021-03-24 13:00:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2737
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [16] => WP_Post Object
                (
                    [ID] => 2736
                    [post_author] => 5
                    [post_date] => 2021-03-23 18:15:15
                    [post_date_gmt] => 2021-03-23 18:15:15
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-23 18:15:15
                    [post_modified_gmt] => 2021-03-23 18:15:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2736
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [17] => WP_Post Object
                (
                    [ID] => 2735
                    [post_author] => 5
                    [post_date] => 2021-03-23 18:05:28
                    [post_date_gmt] => 2021-03-23 18:05:28
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-23 18:05:28
                    [post_modified_gmt] => 2021-03-23 18:05:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2735
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [18] => WP_Post Object
                (
                    [ID] => 2734
                    [post_author] => 5
                    [post_date] => 2021-03-23 18:01:22
                    [post_date_gmt] => 2021-03-23 18:01:22
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of Covid-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-23 18:01:38
                    [post_modified_gmt] => 2021-03-23 18:01:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2734
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [19] => WP_Post Object
                (
                    [ID] => 2543
                    [post_author] => 5
                    [post_date] => 2021-03-12 18:15:58
                    [post_date_gmt] => 2021-03-12 18:15:58
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 18:15:58
                    [post_modified_gmt] => 2021-03-12 18:15:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2543
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [20] => WP_Post Object
                (
                    [ID] => 2540
                    [post_author] => 5
                    [post_date] => 2021-03-12 18:12:48
                    [post_date_gmt] => 2021-03-12 18:12:48
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 18:12:48
                    [post_modified_gmt] => 2021-03-12 18:12:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2540
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [21] => WP_Post Object
                (
                    [ID] => 2541
                    [post_author] => 5
                    [post_date] => 2021-03-12 18:11:14
                    [post_date_gmt] => 2021-03-12 18:11:14
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 18:11:14
                    [post_modified_gmt] => 2021-03-12 18:11:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2541
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [22] => WP_Post Object
                (
                    [ID] => 2542
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:21:07
                    [post_date_gmt] => 2021-03-12 14:21:07
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 15:00:22
                    [post_modified_gmt] => 2021-03-12 15:00:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2542
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [23] => WP_Post Object
                (
                    [ID] => 2544
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:16:06
                    [post_date_gmt] => 2021-03-12 14:16:06
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 14:16:06
                    [post_modified_gmt] => 2021-03-12 14:16:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2544
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [24] => WP_Post Object
                (
                    [ID] => 2545
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:14:38
                    [post_date_gmt] => 2021-03-12 14:14:38
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 14:14:38
                    [post_modified_gmt] => 2021-03-12 14:14:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2545
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [25] => WP_Post Object
                (
                    [ID] => 2546
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:13:16
                    [post_date_gmt] => 2021-03-12 14:13:16
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 14:13:16
                    [post_modified_gmt] => 2021-03-12 14:13:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2546
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [26] => WP_Post Object
                (
                    [ID] => 2547
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:58:55
                    [post_date_gmt] => 2021-03-12 13:58:55
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 14:10:14
                    [post_modified_gmt] => 2021-03-12 14:10:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2547
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [27] => WP_Post Object
                (
                    [ID] => 2548
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:55:59
                    [post_date_gmt] => 2021-03-12 13:55:59
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 13:55:59
                    [post_modified_gmt] => 2021-03-12 13:55:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2548
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [28] => WP_Post Object
                (
                    [ID] => 2549
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:50:41
                    [post_date_gmt] => 2021-03-12 13:50:41
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 13:52:46
                    [post_modified_gmt] => 2021-03-12 13:52:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2549
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [29] => WP_Post Object
                (
                    [ID] => 2553
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:47:42
                    [post_date_gmt] => 2021-03-12 13:47:42
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 13:49:04
                    [post_modified_gmt] => 2021-03-12 13:49:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2553
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [30] => WP_Post Object
                (
                    [ID] => 2554
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:44:47
                    [post_date_gmt] => 2021-03-12 13:44:47
                    [post_content] => 
                    [post_title] => AstraZeneca EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-12 13:49:36
                    [post_modified_gmt] => 2021-03-12 13:49:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2554
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [31] => WP_Post Object
                (
                    [ID] => 2457
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:25:57
                    [post_date_gmt] => 2021-02-25 15:25:57
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:25:57
                    [post_modified_gmt] => 2021-02-25 15:25:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2457
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [32] => WP_Post Object
                (
                    [ID] => 2459
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:25:31
                    [post_date_gmt] => 2021-02-25 15:25:31
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:25:31
                    [post_modified_gmt] => 2021-02-25 15:25:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2459
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [33] => WP_Post Object
                (
                    [ID] => 2460
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:23:51
                    [post_date_gmt] => 2021-02-25 15:23:51
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:23:51
                    [post_modified_gmt] => 2021-02-25 15:23:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2460
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [34] => WP_Post Object
                (
                    [ID] => 2461
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:23:35
                    [post_date_gmt] => 2021-02-25 15:23:35
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:23:35
                    [post_modified_gmt] => 2021-02-25 15:23:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2461
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [35] => WP_Post Object
                (
                    [ID] => 2462
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:23:19
                    [post_date_gmt] => 2021-02-25 15:23:19
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:23:19
                    [post_modified_gmt] => 2021-02-25 15:23:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2462
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [36] => WP_Post Object
                (
                    [ID] => 2463
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:22:52
                    [post_date_gmt] => 2021-02-25 15:22:52
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:22:52
                    [post_modified_gmt] => 2021-02-25 15:22:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2463
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [37] => WP_Post Object
                (
                    [ID] => 2464
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:21:51
                    [post_date_gmt] => 2021-02-25 15:21:51
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:21:51
                    [post_modified_gmt] => 2021-02-25 15:21:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2464
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [38] => WP_Post Object
                (
                    [ID] => 2465
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:21:32
                    [post_date_gmt] => 2021-02-25 15:21:32
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:21:32
                    [post_modified_gmt] => 2021-02-25 15:21:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2465
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [39] => WP_Post Object
                (
                    [ID] => 2466
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:20:40
                    [post_date_gmt] => 2021-02-25 15:20:40
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:20:40
                    [post_modified_gmt] => 2021-02-25 15:20:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2466
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [40] => WP_Post Object
                (
                    [ID] => 2467
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:20:15
                    [post_date_gmt] => 2021-02-25 15:20:15
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:20:15
                    [post_modified_gmt] => 2021-02-25 15:20:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [41] => WP_Post Object
                (
                    [ID] => 2470
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:24:13
                    [post_date_gmt] => 2021-01-25 13:24:13
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:24:13
                    [post_modified_gmt] => 2021-01-25 13:24:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2470
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [42] => WP_Post Object
                (
                    [ID] => 2472
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:23:03
                    [post_date_gmt] => 2021-01-25 13:23:03
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:23:03
                    [post_modified_gmt] => 2021-01-25 13:23:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2472
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [43] => WP_Post Object
                (
                    [ID] => 2473
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:21:58
                    [post_date_gmt] => 2021-01-25 13:21:58
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:21:58
                    [post_modified_gmt] => 2021-01-25 13:21:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2473
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [44] => WP_Post Object
                (
                    [ID] => 2474
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:19:34
                    [post_date_gmt] => 2021-01-25 13:19:34
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:19:34
                    [post_modified_gmt] => 2021-01-25 13:19:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2474
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [45] => WP_Post Object
                (
                    [ID] => 2475
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:18:53
                    [post_date_gmt] => 2021-01-25 13:18:53
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:18:53
                    [post_modified_gmt] => 2021-01-25 13:18:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2475
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [46] => WP_Post Object
                (
                    [ID] => 2476
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:18:09
                    [post_date_gmt] => 2021-01-25 13:18:09
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:18:09
                    [post_modified_gmt] => 2021-01-25 13:18:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2476
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [47] => WP_Post Object
                (
                    [ID] => 2477
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:16:23
                    [post_date_gmt] => 2021-01-25 13:16:23
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:16:23
                    [post_modified_gmt] => 2021-01-25 13:16:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2477
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [48] => WP_Post Object
                (
                    [ID] => 2478
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:14:33
                    [post_date_gmt] => 2021-01-25 13:14:33
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:14:33
                    [post_modified_gmt] => 2021-01-25 13:14:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2478
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [49] => WP_Post Object
                (
                    [ID] => 2479
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:12:32
                    [post_date_gmt] => 2021-01-25 13:12:32
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:12:32
                    [post_modified_gmt] => 2021-01-25 13:12:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2479
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [50] => WP_Post Object
                (
                    [ID] => 2480
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:11:47
                    [post_date_gmt] => 2021-01-25 13:11:47
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:11:47
                    [post_modified_gmt] => 2021-01-25 13:11:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2480
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [51] => WP_Post Object
                (
                    [ID] => 2481
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:11:08
                    [post_date_gmt] => 2021-01-25 13:11:08
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:11:08
                    [post_modified_gmt] => 2021-01-25 13:11:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2481
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [52] => WP_Post Object
                (
                    [ID] => 2482
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:09:37
                    [post_date_gmt] => 2021-01-25 13:09:37
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:09:37
                    [post_modified_gmt] => 2021-01-25 13:09:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2482
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [53] => WP_Post Object
                (
                    [ID] => 2483
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:08:51
                    [post_date_gmt] => 2021-01-25 13:08:51
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:08:51
                    [post_modified_gmt] => 2021-01-25 13:08:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2483
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [54] => WP_Post Object
                (
                    [ID] => 2471
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:08:02
                    [post_date_gmt] => 2021-01-25 13:08:02
                    [post_content] => 
                    [post_title] => CureVac EC Covid-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:08:02
                    [post_modified_gmt] => 2021-01-25 13:08:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2471
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [55] => WP_Post Object
                (
                    [ID] => 2454
                    [post_author] => 5
                    [post_date] => 2021-01-19 11:44:16
                    [post_date_gmt] => 2021-01-19 11:44:16
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-19 11:44:16
                    [post_modified_gmt] => 2021-01-19 11:44:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2454
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [56] => WP_Post Object
                (
                    [ID] => 2452
                    [post_author] => 5
                    [post_date] => 2021-01-19 11:41:19
                    [post_date_gmt] => 2021-01-19 11:41:19
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-19 11:41:19
                    [post_modified_gmt] => 2021-01-19 11:41:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2452
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [57] => WP_Post Object
                (
                    [ID] => 2450
                    [post_author] => 5
                    [post_date] => 2021-01-19 11:04:23
                    [post_date_gmt] => 2021-01-19 11:04:23
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-19 11:04:23
                    [post_modified_gmt] => 2021-01-19 11:04:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2450
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [58] => WP_Post Object
                (
                    [ID] => 2449
                    [post_author] => 5
                    [post_date] => 2021-01-19 10:47:27
                    [post_date_gmt] => 2021-01-19 10:47:27
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-19 10:47:27
                    [post_modified_gmt] => 2021-01-19 10:47:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2449
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [59] => WP_Post Object
                (
                    [ID] => 2448
                    [post_author] => 5
                    [post_date] => 2021-01-19 10:24:45
                    [post_date_gmt] => 2021-01-19 10:24:45
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-19 10:24:45
                    [post_modified_gmt] => 2021-01-19 10:24:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2448
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [60] => WP_Post Object
                (
                    [ID] => 2445
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:31:14
                    [post_date_gmt] => 2021-01-19 09:31:14
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-19 09:31:14
                    [post_modified_gmt] => 2021-01-19 09:31:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2445
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [61] => WP_Post Object
                (
                    [ID] => 2444
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:27:20
                    [post_date_gmt] => 2021-01-19 09:27:20
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-19 09:27:20
                    [post_modified_gmt] => 2021-01-19 09:27:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [62] => WP_Post Object
                (
                    [ID] => 2443
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:14:03
                    [post_date_gmt] => 2021-01-19 09:14:03
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-19 09:14:03
                    [post_modified_gmt] => 2021-01-19 09:14:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2443
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [63] => WP_Post Object
                (
                    [ID] => 2442
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:56:32
                    [post_date_gmt] => 2021-01-19 06:56:32
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-19 06:56:32
                    [post_modified_gmt] => 2021-01-19 06:56:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2442
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [64] => WP_Post Object
                (
                    [ID] => 2441
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:48:04
                    [post_date_gmt] => 2021-01-19 06:48:04
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-19 06:48:04
                    [post_modified_gmt] => 2021-01-19 06:48:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2441
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [65] => WP_Post Object
                (
                    [ID] => 2440
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:45:33
                    [post_date_gmt] => 2021-01-19 06:45:33
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-19 06:45:33
                    [post_modified_gmt] => 2021-01-19 06:45:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2440
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [66] => WP_Post Object
                (
                    [ID] => 2425
                    [post_author] => 5
                    [post_date] => 2020-12-14 15:02:33
                    [post_date_gmt] => 2020-12-14 15:02:33
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-22 12:13:42
                    [post_modified_gmt] => 2021-01-22 12:13:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2425
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [67] => WP_Post Object
                (
                    [ID] => 2426
                    [post_author] => 5
                    [post_date] => 2020-12-14 15:02:08
                    [post_date_gmt] => 2020-12-14 15:02:08
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-12-22 13:52:16
                    [post_modified_gmt] => 2020-12-22 13:52:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2426
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [68] => WP_Post Object
                (
                    [ID] => 2424
                    [post_author] => 5
                    [post_date] => 2020-12-14 15:01:40
                    [post_date_gmt] => 2020-12-14 15:01:40
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-12-22 13:51:02
                    [post_modified_gmt] => 2020-12-22 13:51:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2424
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [69] => WP_Post Object
                (
                    [ID] => 2422
                    [post_author] => 5
                    [post_date] => 2020-12-14 14:59:29
                    [post_date_gmt] => 2020-12-14 14:59:29
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-25 13:37:01
                    [post_modified_gmt] => 2021-01-25 13:37:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2422
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [70] => WP_Post Object
                (
                    [ID] => 1395
                    [post_author] => 7
                    [post_date] => 2020-05-30 21:25:33
                    [post_date_gmt] => 2020-05-30 21:25:33
                    [post_content] => 
                    [post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:28:33
                    [post_modified_gmt] => 2020-08-06 08:28:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1395
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [71] => WP_Post Object
                (
                    [ID] => 1394
                    [post_author] => 7
                    [post_date] => 2020-05-30 21:22:44
                    [post_date_gmt] => 2020-05-30 21:22:44
                    [post_content] => 
                    [post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:40:24
                    [post_modified_gmt] => 2020-08-06 05:40:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1394
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [72] => WP_Post Object
                (
                    [ID] => 1393
                    [post_author] => 7
                    [post_date] => 2020-05-30 20:13:50
                    [post_date_gmt] => 2020-05-30 20:13:50
                    [post_content] => 
                    [post_title] => Gates Foundation Open Access Policy
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 1393
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 04:49:54
                    [post_modified_gmt] => 2020-08-06 04:49:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1393
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [73] => WP_Post Object
                (
                    [ID] => 1315
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:56:03
                    [post_date_gmt] => 2020-05-23 17:56:03
                    [post_content] => 
                    [post_title] => MPP License Agreement with ViiV on Dolutegravir for Adults
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-10-10 22:05:56
                    [post_modified_gmt] => 2020-10-10 22:05:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1315
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [74] => WP_Post Object
                (
                    [ID] => 1313
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:55:00
                    [post_date_gmt] => 2020-05-23 17:55:00
                    [post_content] => 
                    [post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-04 05:11:03
                    [post_modified_gmt] => 2020-08-04 05:11:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1313
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [75] => WP_Post Object
                (
                    [ID] => 1314
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:54:57
                    [post_date_gmt] => 2020-05-23 17:54:57
                    [post_content] => 
                    [post_title] => MPP Amended and Restated Sublicense and Technology Transfer Agreement under BMS-MPP License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-10-10 22:08:33
                    [post_modified_gmt] => 2020-10-10 22:08:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1314
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [76] => WP_Post Object
                (
                    [ID] => 1308
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:17:48
                    [post_date_gmt] => 2020-05-23 17:17:48
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 04:59:05
                    [post_modified_gmt] => 2020-08-06 04:59:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1308
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [77] => WP_Post Object
                (
                    [ID] => 1309
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:17:44
                    [post_date_gmt] => 2020-05-23 17:17:44
                    [post_content] => 
                    [post_title] => IMI 2Joint Undertaking  Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2joint-undertaking-model-consortium-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 04:59:37
                    [post_modified_gmt] => 2020-08-06 04:59:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1309
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [78] => WP_Post Object
                (
                    [ID] => 1311
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:12:09
                    [post_date_gmt] => 2020-05-23 17:12:09
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:43:06
                    [post_modified_gmt] => 2020-08-06 05:43:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1311
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [79] => WP_Post Object
                (
                    [ID] => 1310
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:12:02
                    [post_date_gmt] => 2020-05-23 17:12:02
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:30:05
                    [post_modified_gmt] => 2020-08-06 08:30:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1310
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [80] => WP_Post Object
                (
                    [ID] => 1307
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:05:21
                    [post_date_gmt] => 2020-05-23 17:05:21
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-10-10 22:20:30
                    [post_modified_gmt] => 2020-10-10 22:20:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1307
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [81] => WP_Post Object
                (
                    [ID] => 1306
                    [post_author] => 7
                    [post_date] => 2020-05-23 16:57:14
                    [post_date_gmt] => 2020-05-23 16:57:14
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:45:45
                    [post_modified_gmt] => 2020-08-06 05:45:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1306
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [82] => WP_Post Object
                (
                    [ID] => 1305
                    [post_author] => 7
                    [post_date] => 2020-05-23 16:51:40
                    [post_date_gmt] => 2020-05-23 16:51:40
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 1305
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-10-10 22:21:50
                    [post_modified_gmt] => 2020-10-10 22:21:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1305
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [83] => WP_Post Object
                (
                    [ID] => 1304
                    [post_author] => 7
                    [post_date] => 2020-05-23 16:46:37
                    [post_date_gmt] => 2020-05-23 16:46:37
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:47:49
                    [post_modified_gmt] => 2020-08-06 05:47:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1304
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [84] => WP_Post Object
                (
                    [ID] => 1303
                    [post_author] => 7
                    [post_date] => 2020-05-23 16:46:30
                    [post_date_gmt] => 2020-05-23 16:46:30
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:48:31
                    [post_modified_gmt] => 2020-08-06 05:48:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1303
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [85] => WP_Post Object
                (
                    [ID] => 1296
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:46:47
                    [post_date_gmt] => 2020-05-22 23:46:47
                    [post_content] => 
                    [post_title] => WHO
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:49:42
                    [post_modified_gmt] => 2020-08-06 05:49:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1296
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [86] => WP_Post Object
                (
                    [ID] => 1291
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:42:19
                    [post_date_gmt] => 2020-05-22 23:42:19
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-10-10 22:25:11
                    [post_modified_gmt] => 2020-10-10 22:25:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1291
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [87] => WP_Post Object
                (
                    [ID] => 1293
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:42:02
                    [post_date_gmt] => 2020-05-22 23:42:02
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:50:33
                    [post_modified_gmt] => 2020-08-06 05:50:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1293
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [88] => WP_Post Object
                (
                    [ID] => 1288
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:31:30
                    [post_date_gmt] => 2020-05-22 23:31:30
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:15:24
                    [post_modified_gmt] => 2020-08-06 19:15:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1288
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [89] => WP_Post Object
                (
                    [ID] => 1287
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:05:30
                    [post_date_gmt] => 2020-05-22 23:05:30
                    [post_content] => 
                    [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-07 14:11:07
                    [post_modified_gmt] => 2020-08-07 14:11:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1287
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [90] => WP_Post Object
                (
                    [ID] => 1285
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:01:07
                    [post_date_gmt] => 2020-05-22 23:01:07
                    [post_content] => 
                    [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:55:08
                    [post_modified_gmt] => 2020-08-06 05:55:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1285
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [91] => WP_Post Object
                (
                    [ID] => 1284
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:58:55
                    [post_date_gmt] => 2020-05-22 22:58:55
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:55:57
                    [post_modified_gmt] => 2020-08-06 05:55:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1284
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [92] => WP_Post Object
                (
                    [ID] => 1283
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:57:44
                    [post_date_gmt] => 2020-05-22 22:57:44
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:56:15
                    [post_modified_gmt] => 2020-08-06 05:56:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1283
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [93] => WP_Post Object
                (
                    [ID] => 1282
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:56:18
                    [post_date_gmt] => 2020-05-22 22:56:18
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:56:57
                    [post_modified_gmt] => 2020-08-06 05:56:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1282
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [94] => WP_Post Object
                (
                    [ID] => 1281
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:55:22
                    [post_date_gmt] => 2020-05-22 22:55:22
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:57:24
                    [post_modified_gmt] => 2020-08-06 05:57:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1281
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [95] => WP_Post Object
                (
                    [ID] => 1280
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:54:32
                    [post_date_gmt] => 2020-05-22 22:54:32
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm-model-iia-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:57:59
                    [post_modified_gmt] => 2020-08-06 05:57:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1280
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [96] => WP_Post Object
                (
                    [ID] => 1276
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:40:34
                    [post_date_gmt] => 2020-05-22 22:40:34
                    [post_content] => 
                    [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:58:18
                    [post_modified_gmt] => 2020-08-06 05:58:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1276
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [97] => WP_Post Object
                (
                    [ID] => 1275
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:39:41
                    [post_date_gmt] => 2020-05-22 22:39:41
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:58:40
                    [post_modified_gmt] => 2020-08-06 05:58:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1275
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [98] => WP_Post Object
                (
                    [ID] => 1274
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:38:47
                    [post_date_gmt] => 2020-05-22 22:38:47
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:59:08
                    [post_modified_gmt] => 2020-08-06 05:59:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1274
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [99] => WP_Post Object
                (
                    [ID] => 1273
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:37:54
                    [post_date_gmt] => 2020-05-22 22:37:54
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm-model-iia-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-04 04:20:47
                    [post_modified_gmt] => 2020-08-04 04:20:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1273
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [100] => WP_Post Object
                (
                    [ID] => 1272
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:36:39
                    [post_date_gmt] => 2020-05-22 22:36:39
                    [post_content] => 
                    [post_title] => BU Startup Exclusive License
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bu-startup-exclusive-license-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:59:41
                    [post_modified_gmt] => 2020-08-06 05:59:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1272
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [101] => WP_Post Object
                (
                    [ID] => 1271
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:34:12
                    [post_date_gmt] => 2020-05-22 22:34:12
                    [post_content] => 
                    [post_title] => WHO Standard Framework Memorandum of Understanding
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-standard-framework-memorandum-of-understanding-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:00:10
                    [post_modified_gmt] => 2020-08-06 06:00:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1271
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [102] => WP_Post Object
                (
                    [ID] => 1270
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:32:29
                    [post_date_gmt] => 2020-05-22 22:32:29
                    [post_content] => 
                    [post_title] => MPP License Agreement with Gilead
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-gilead-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-10-18 11:46:22
                    [post_modified_gmt] => 2020-10-18 11:46:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1270
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [103] => WP_Post Object
                (
                    [ID] => 1269
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:29:54
                    [post_date_gmt] => 2020-05-22 22:29:54
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:01:05
                    [post_modified_gmt] => 2020-08-06 06:01:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1269
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [104] => WP_Post Object
                (
                    [ID] => 1268
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:27:54
                    [post_date_gmt] => 2020-05-22 22:27:54
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:01:30
                    [post_modified_gmt] => 2020-08-06 06:01:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1268
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [105] => WP_Post Object
                (
                    [ID] => 1267
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:26:39
                    [post_date_gmt] => 2020-05-22 22:26:39
                    [post_content] => 
                    [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:02:22
                    [post_modified_gmt] => 2020-08-06 06:02:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1267
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [106] => WP_Post Object
                (
                    [ID] => 1266
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:25:16
                    [post_date_gmt] => 2020-05-22 22:25:16
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:03:25
                    [post_modified_gmt] => 2020-08-06 06:03:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1266
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [107] => WP_Post Object
                (
                    [ID] => 1265
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:24:11
                    [post_date_gmt] => 2020-05-22 22:24:11
                    [post_content] => 
                    [post_title] => WHO Template Material Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-template-material-transfer-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:03:50
                    [post_modified_gmt] => 2020-08-06 06:03:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1265
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [108] => WP_Post Object
                (
                    [ID] => 1264
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:22:55
                    [post_date_gmt] => 2020-05-22 22:22:55
                    [post_content] => 
                    [post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:04:26
                    [post_modified_gmt] => 2020-08-06 06:04:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1264
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [109] => WP_Post Object
                (
                    [ID] => 1263
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:20:56
                    [post_date_gmt] => 2020-05-22 22:20:56
                    [post_content] => 
                    [post_title] => MPP License Agreement with Gilead
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-gilead-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:21:52
                    [post_modified_gmt] => 2020-08-06 19:21:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1263
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [110] => WP_Post Object
                (
                    [ID] => 1262
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:18:41
                    [post_date_gmt] => 2020-05-22 22:18:41
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:05:46
                    [post_modified_gmt] => 2020-08-06 06:05:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1262
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [111] => WP_Post Object
                (
                    [ID] => 1261
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:17:34
                    [post_date_gmt] => 2020-05-22 22:17:34
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:06:36
                    [post_modified_gmt] => 2020-08-06 06:06:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1261
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [112] => WP_Post Object
                (
                    [ID] => 1259
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:04:31
                    [post_date_gmt] => 2020-05-22 22:04:31
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:06:50
                    [post_modified_gmt] => 2020-08-06 06:06:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1259
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [113] => WP_Post Object
                (
                    [ID] => 1258
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:03:08
                    [post_date_gmt] => 2020-05-22 22:03:08
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:07:40
                    [post_modified_gmt] => 2020-08-06 06:07:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1258
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [114] => WP_Post Object
                (
                    [ID] => 1257
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:54:08
                    [post_date_gmt] => 2020-05-22 21:54:08
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:08:19
                    [post_modified_gmt] => 2020-08-06 06:08:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1257
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [115] => WP_Post Object
                (
                    [ID] => 1255
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:49:26
                    [post_date_gmt] => 2020-05-22 21:49:26
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:09:08
                    [post_modified_gmt] => 2020-08-06 06:09:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1255
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [116] => WP_Post Object
                (
                    [ID] => 1254
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:44:49
                    [post_date_gmt] => 2020-05-22 21:44:49
                    [post_content] => 
                    [post_title] => Gates Foundation Data & Materials Sharing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-data-materials-sharing-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:09:56
                    [post_modified_gmt] => 2020-08-06 06:09:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1254
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [117] => WP_Post Object
                (
                    [ID] => 1253
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:42:28
                    [post_date_gmt] => 2020-05-22 21:42:28
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:38:41
                    [post_modified_gmt] => 2020-08-06 19:38:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1253
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [118] => WP_Post Object
                (
                    [ID] => 1252
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:41:17
                    [post_date_gmt] => 2020-05-22 21:41:17
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:25:32
                    [post_modified_gmt] => 2020-08-06 06:25:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1252
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [119] => WP_Post Object
                (
                    [ID] => 1251
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:39:48
                    [post_date_gmt] => 2020-05-22 21:39:48
                    [post_content] => 
                    [post_title] => CAVD Data & Materials Sharing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cavd-data-materials-sharing-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:40:50
                    [post_modified_gmt] => 2020-08-06 19:40:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1251
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [120] => WP_Post Object
                (
                    [ID] => 1250
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:38:31
                    [post_date_gmt] => 2020-05-22 21:38:31
                    [post_content] => 
                    [post_title] => CAVD Data & Materials Sharing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cavd-data-materials-sharing-agreement-2-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:41:55
                    [post_modified_gmt] => 2020-08-06 19:41:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1250
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [121] => WP_Post Object
                (
                    [ID] => 1249
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:37:42
                    [post_date_gmt] => 2020-05-22 21:37:42
                    [post_content] => 
                    [post_title] => MPP License Agreement with Gilead
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-gilead-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:22:26
                    [post_modified_gmt] => 2020-08-06 06:22:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1249
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [122] => WP_Post Object
                (
                    [ID] => 1248
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:36:47
                    [post_date_gmt] => 2020-05-22 21:36:47
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:19:18
                    [post_modified_gmt] => 2020-08-06 06:19:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1248
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [123] => WP_Post Object
                (
                    [ID] => 1247
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:33:54
                    [post_date_gmt] => 2020-05-22 21:33:54
                    [post_content] => 
                    [post_title] => WHO Mutual Confidential Disclosure Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-mutual-confidential-disclosure-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:18:47
                    [post_modified_gmt] => 2020-08-06 06:18:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1247
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [124] => WP_Post Object
                (
                    [ID] => 1245
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:32:14
                    [post_date_gmt] => 2020-05-22 21:32:14
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:17:49
                    [post_modified_gmt] => 2020-08-06 06:17:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1245
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [125] => WP_Post Object
                (
                    [ID] => 1244
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:30:57
                    [post_date_gmt] => 2020-05-22 21:30:57
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:16:51
                    [post_modified_gmt] => 2020-08-06 06:16:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1244
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [126] => WP_Post Object
                (
                    [ID] => 1243
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:29:10
                    [post_date_gmt] => 2020-05-22 21:29:10
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm-model-iia-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:15:56
                    [post_modified_gmt] => 2020-08-06 06:15:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1243
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [127] => WP_Post Object
                (
                    [ID] => 1242
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:26:04
                    [post_date_gmt] => 2020-05-22 21:26:04
                    [post_content] => 
                    [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:45:06
                    [post_modified_gmt] => 2020-08-06 19:45:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1242
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [128] => WP_Post Object
                (
                    [ID] => 1241
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:24:25
                    [post_date_gmt] => 2020-05-22 21:24:25
                    [post_content] => 
                    [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:13:20
                    [post_modified_gmt] => 2020-08-06 06:13:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1241
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [129] => WP_Post Object
                (
                    [ID] => 1240
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:22:47
                    [post_date_gmt] => 2020-05-22 21:22:47
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:11:52
                    [post_modified_gmt] => 2020-08-06 06:11:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1240
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [130] => WP_Post Object
                (
                    [ID] => 1239
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:21:49
                    [post_date_gmt] => 2020-05-22 21:21:49
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:27:18
                    [post_modified_gmt] => 2020-08-06 06:27:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1239
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [131] => WP_Post Object
                (
                    [ID] => 1238
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:20:51
                    [post_date_gmt] => 2020-05-22 21:20:51
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:29:07
                    [post_modified_gmt] => 2020-08-06 06:29:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1238
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [132] => WP_Post Object
                (
                    [ID] => 1237
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:19:08
                    [post_date_gmt] => 2020-05-22 21:19:08
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:29:51
                    [post_modified_gmt] => 2020-08-06 06:29:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1237
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [133] => WP_Post Object
                (
                    [ID] => 1236
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:17:57
                    [post_date_gmt] => 2020-05-22 21:17:57
                    [post_content] => 
                    [post_title] => WHO Template Material Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-template-material-transfer-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:30:25
                    [post_modified_gmt] => 2020-08-06 06:30:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1236
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [134] => WP_Post Object
                (
                    [ID] => 1235
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:01:14
                    [post_date_gmt] => 2020-05-22 21:01:14
                    [post_content] => 
                    [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:33:13
                    [post_modified_gmt] => 2020-08-06 06:33:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1235
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [135] => WP_Post Object
                (
                    [ID] => 1233
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:00:08
                    [post_date_gmt] => 2020-05-22 21:00:08
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:49:06
                    [post_modified_gmt] => 2020-08-06 19:49:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1233
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [136] => WP_Post Object
                (
                    [ID] => 1232
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:57:46
                    [post_date_gmt] => 2020-05-22 20:57:46
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:35:49
                    [post_modified_gmt] => 2020-08-06 06:35:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1232
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [137] => WP_Post Object
                (
                    [ID] => 1231
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:54:50
                    [post_date_gmt] => 2020-05-22 20:54:50
                    [post_content] => 
                    [post_title] => CAVD Data & Materials Sharing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cavd-data-materials-sharing-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:37:41
                    [post_modified_gmt] => 2020-08-06 06:37:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1231
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [138] => WP_Post Object
                (
                    [ID] => 1229
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:51:35
                    [post_date_gmt] => 2020-05-22 20:51:35
                    [post_content] => 
                    [post_title] => MPP License Agreement with BMS & Aurobindo Pharma Ltd.
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:39:20
                    [post_modified_gmt] => 2020-08-06 06:39:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1229
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [139] => WP_Post Object
                (
                    [ID] => 1228
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:49:20
                    [post_date_gmt] => 2020-05-22 20:49:20
                    [post_content] => 
                    [post_title] => MPP License Agreement with Gilead
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-gilead-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:52:03
                    [post_modified_gmt] => 2020-08-06 19:52:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1228
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [140] => WP_Post Object
                (
                    [ID] => 1227
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:48:27
                    [post_date_gmt] => 2020-05-22 20:48:27
                    [post_content] => 
                    [post_title] => Ebola WHO-Manufacturer LOA (Annex)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ebola-who-manufacturer-loa-annex
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:52:47
                    [post_modified_gmt] => 2020-08-06 19:52:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1227
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [141] => WP_Post Object
                (
                    [ID] => 1226
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:47:05
                    [post_date_gmt] => 2020-05-22 20:47:05
                    [post_content] => 
                    [post_title] => WHO Template Material Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-template-material-transfer-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:44:21
                    [post_modified_gmt] => 2020-08-06 06:44:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1226
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [142] => WP_Post Object
                (
                    [ID] => 1225
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:43:20
                    [post_date_gmt] => 2020-05-22 20:43:20
                    [post_content] => 
                    [post_title] => WHO Template Material Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-template-material-transfer-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:45:39
                    [post_modified_gmt] => 2020-08-06 06:45:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1225
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [143] => WP_Post Object
                (
                    [ID] => 1223
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:14:40
                    [post_date_gmt] => 2020-05-22 20:14:40
                    [post_content] => 
                    [post_title] => Ten Principles for Socially Responsible Licensing, by Netherlands Federation of University Medical Centers (June 2019)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:46:21
                    [post_modified_gmt] => 2020-08-06 06:46:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1223
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [144] => WP_Post Object
                (
                    [ID] => 1222
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:12:04
                    [post_date_gmt] => 2020-05-22 20:12:04
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfpi3-template-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:47:07
                    [post_modified_gmt] => 2020-08-06 06:47:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1222
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [145] => WP_Post Object
                (
                    [ID] => 1221
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:09:53
                    [post_date_gmt] => 2020-05-22 20:09:53
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfpi3-template-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:55:03
                    [post_modified_gmt] => 2020-08-06 19:55:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [146] => WP_Post Object
                (
                    [ID] => 1220
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:05:59
                    [post_date_gmt] => 2020-05-22 20:05:59
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:48:16
                    [post_modified_gmt] => 2020-08-06 06:48:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1220
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [147] => WP_Post Object
                (
                    [ID] => 1218
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:04:53
                    [post_date_gmt] => 2020-05-22 20:04:53
                    [post_content] => 
                    [post_title] => CARB-X Research Subaward Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:57:30
                    [post_modified_gmt] => 2020-08-06 19:57:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1218
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [148] => WP_Post Object
                (
                    [ID] => 1217
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:00:26
                    [post_date_gmt] => 2020-05-22 20:00:26
                    [post_content] => 
                    [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => edctp2-policy-on-clinical-trials-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:16:02
                    [post_modified_gmt] => 2020-08-06 07:16:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1217
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [149] => WP_Post Object
                (
                    [ID] => 1216
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:58:08
                    [post_date_gmt] => 2020-05-22 19:58:08
                    [post_content] => 
                    [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => edctp2-policy-on-clinical-trials
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:54:51
                    [post_modified_gmt] => 2020-08-06 06:54:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1216
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [150] => WP_Post Object
                (
                    [ID] => 1215
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:56:47
                    [post_date_gmt] => 2020-05-22 19:56:47
                    [post_content] => 
                    [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => edctp2-policy-on-clinical-trials-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:56:31
                    [post_modified_gmt] => 2020-08-06 06:56:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1215
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [151] => WP_Post Object
                (
                    [ID] => 1214
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:55:41
                    [post_date_gmt] => 2020-05-22 19:55:41
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:57:53
                    [post_modified_gmt] => 2020-08-06 06:57:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1214
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [152] => WP_Post Object
                (
                    [ID] => 1211
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:50:22
                    [post_date_gmt] => 2020-05-22 19:50:22
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:58:52
                    [post_modified_gmt] => 2020-08-06 06:58:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1211
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [153] => WP_Post Object
                (
                    [ID] => 1210
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:49:19
                    [post_date_gmt] => 2020-05-22 19:49:19
                    [post_content] => 
                    [post_title] => Ten Principles for Socially Responsible Licensing, by Netherlands Federation of University Medical Centers (June 2019)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:59:22
                    [post_modified_gmt] => 2020-08-06 06:59:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1210
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [154] => WP_Post Object
                (
                    [ID] => 1207
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:42:36
                    [post_date_gmt] => 2020-05-22 19:42:36
                    [post_content] => 
                    [post_title] => MPP License Agreement with Pfizer re Sutezolid
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-pfizer-re-sutezolid
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:59:52
                    [post_modified_gmt] => 2020-08-06 06:59:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1207
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [155] => WP_Post Object
                (
                    [ID] => 1206
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:37:27
                    [post_date_gmt] => 2020-05-22 19:37:27
                    [post_content] => 
                    [post_title] => Gates Global Access Commitment & Humanitarian License
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-global-access-commitment-and-humanitarian-license
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:00:51
                    [post_modified_gmt] => 2020-08-06 07:00:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [156] => WP_Post Object
                (
                    [ID] => 1200
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:35:05
                    [post_date_gmt] => 2020-05-22 19:35:05
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 20:02:26
                    [post_modified_gmt] => 2020-08-06 20:02:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1200
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [157] => WP_Post Object
                (
                    [ID] => 1205
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:33:17
                    [post_date_gmt] => 2020-05-22 19:33:17
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:04:45
                    [post_modified_gmt] => 2020-08-06 07:04:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [158] => WP_Post Object
                (
                    [ID] => 1204
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:31:46
                    [post_date_gmt] => 2020-05-22 19:31:46
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:06:42
                    [post_modified_gmt] => 2020-08-06 07:06:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [159] => WP_Post Object
                (
                    [ID] => 1203
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:30:52
                    [post_date_gmt] => 2020-05-22 19:30:52
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:07:29
                    [post_modified_gmt] => 2020-08-06 07:07:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [160] => WP_Post Object
                (
                    [ID] => 1202
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:28:49
                    [post_date_gmt] => 2020-05-22 19:28:49
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-09-06 23:38:12
                    [post_modified_gmt] => 2020-09-06 23:38:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [161] => WP_Post Object
                (
                    [ID] => 1201
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:26:29
                    [post_date_gmt] => 2020-05-22 19:26:29
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:09:26
                    [post_modified_gmt] => 2020-08-06 07:09:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1201
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [162] => WP_Post Object
                (
                    [ID] => 1199
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:21:57
                    [post_date_gmt] => 2020-05-22 19:21:57
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:11:10
                    [post_modified_gmt] => 2020-08-06 07:11:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1199
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [163] => WP_Post Object
                (
                    [ID] => 1198
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:12:54
                    [post_date_gmt] => 2020-05-22 19:12:54
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:12:41
                    [post_modified_gmt] => 2020-08-06 07:12:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1198
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [164] => WP_Post Object
                (
                    [ID] => 1193
                    [post_author] => 6
                    [post_date] => 2020-05-22 02:10:10
                    [post_date_gmt] => 2020-05-22 02:10:10
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-04 04:18:05
                    [post_modified_gmt] => 2020-08-04 04:18:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1193
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [165] => WP_Post Object
                (
                    [ID] => 1190
                    [post_author] => 6
                    [post_date] => 2020-05-22 01:59:48
                    [post_date_gmt] => 2020-05-22 01:59:48
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:13:53
                    [post_modified_gmt] => 2020-08-06 07:13:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1190
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [166] => WP_Post Object
                (
                    [ID] => 1187
                    [post_author] => 6
                    [post_date] => 2020-05-22 01:56:10
                    [post_date_gmt] => 2020-05-22 01:56:10
                    [post_content] => 
                    [post_title] => CARB-X Research Subaward Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:15:18
                    [post_modified_gmt] => 2020-08-06 07:15:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1187
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [167] => WP_Post Object
                (
                    [ID] => 1186
                    [post_author] => 6
                    [post_date] => 2020-05-22 00:11:20
                    [post_date_gmt] => 2020-05-22 00:11:20
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm-model-iia-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:19:26
                    [post_modified_gmt] => 2020-08-06 07:19:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1186
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [168] => WP_Post Object
                (
                    [ID] => 1185
                    [post_author] => 6
                    [post_date] => 2020-05-22 00:10:01
                    [post_date_gmt] => 2020-05-22 00:10:01
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:19:08
                    [post_modified_gmt] => 2020-08-06 07:19:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1185
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [169] => WP_Post Object
                (
                    [ID] => 1184
                    [post_author] => 6
                    [post_date] => 2020-05-22 00:08:17
                    [post_date_gmt] => 2020-05-22 00:08:17
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-12 17:41:36
                    [post_modified_gmt] => 2021-04-12 17:41:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1184
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [170] => WP_Post Object
                (
                    [ID] => 1183
                    [post_author] => 6
                    [post_date] => 2020-05-22 00:06:26
                    [post_date_gmt] => 2020-05-22 00:06:26
                    [post_content] => 
                    [post_title] => MPP License Agreement with AbbVie (LPV r)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-abbvie
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:20:18
                    [post_modified_gmt] => 2020-08-06 07:20:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1183
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [171] => WP_Post Object
                (
                    [ID] => 1182
                    [post_author] => 6
                    [post_date] => 2020-05-22 00:02:42
                    [post_date_gmt] => 2020-05-22 00:02:42
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm-model-iia-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 20:22:28
                    [post_modified_gmt] => 2020-08-06 20:22:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1182
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [172] => WP_Post Object
                (
                    [ID] => 1179
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:58:21
                    [post_date_gmt] => 2020-05-21 23:58:21
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 20:23:03
                    [post_modified_gmt] => 2020-08-06 20:23:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1179
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [173] => WP_Post Object
                (
                    [ID] => 1178
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:55:50
                    [post_date_gmt] => 2020-05-21 23:55:50
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:23:22
                    [post_modified_gmt] => 2020-08-06 07:23:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1178
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [174] => WP_Post Object
                (
                    [ID] => 1177
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:53:56
                    [post_date_gmt] => 2020-05-21 23:53:56
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:24:45
                    [post_modified_gmt] => 2020-08-06 07:24:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1177
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [175] => WP_Post Object
                (
                    [ID] => 1176
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:52:12
                    [post_date_gmt] => 2020-05-21 23:52:12
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:26:01
                    [post_modified_gmt] => 2020-08-06 07:26:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1176
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [176] => WP_Post Object
                (
                    [ID] => 1175
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:44:57
                    [post_date_gmt] => 2020-05-21 23:44:57
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:28:09
                    [post_modified_gmt] => 2020-08-06 07:28:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1175
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [177] => WP_Post Object
                (
                    [ID] => 1173
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:37:42
                    [post_date_gmt] => 2020-05-21 23:37:42
                    [post_content] => 
                    [post_title] => CARB-X Research Subaward Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 20:28:01
                    [post_modified_gmt] => 2020-08-06 20:28:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1173
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [178] => WP_Post Object
                (
                    [ID] => 1172
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:35:57
                    [post_date_gmt] => 2020-05-21 23:35:57
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:48:07
                    [post_modified_gmt] => 2020-08-06 07:48:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1172
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [179] => WP_Post Object
                (
                    [ID] => 1171
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:33:24
                    [post_date_gmt] => 2020-05-21 23:33:24
                    [post_content] => 
                    [post_title] => IMI 1 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-1-model-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:34:16
                    [post_modified_gmt] => 2020-08-06 07:34:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1171
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [180] => WP_Post Object
                (
                    [ID] => 1170
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:28:59
                    [post_date_gmt] => 2020-05-21 23:28:59
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:46:46
                    [post_modified_gmt] => 2020-08-06 07:46:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1170
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [181] => WP_Post Object
                (
                    [ID] => 1168
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:26:48
                    [post_date_gmt] => 2020-05-21 23:26:48
                    [post_content] => 
                    [post_title] => NIH Model License Agreement for Use by Non-Profit
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-model-license-agreement-for-use-by-non-profit-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:45:59
                    [post_modified_gmt] => 2020-08-06 07:45:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1168
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [182] => WP_Post Object
                (
                    [ID] => 1166
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:26:07
                    [post_date_gmt] => 2020-05-21 23:26:07
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:45:40
                    [post_modified_gmt] => 2020-08-06 07:45:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1166
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [183] => WP_Post Object
                (
                    [ID] => 1165
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:23:57
                    [post_date_gmt] => 2020-05-21 23:23:57
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:44:57
                    [post_modified_gmt] => 2020-08-06 07:44:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1165
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [184] => WP_Post Object
                (
                    [ID] => 1164
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:22:37
                    [post_date_gmt] => 2020-05-21 23:22:37
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm-model-iia
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 20:30:07
                    [post_modified_gmt] => 2020-08-06 20:30:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1164
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [185] => WP_Post Object
                (
                    [ID] => 1162
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:19:43
                    [post_date_gmt] => 2020-05-21 23:19:43
                    [post_content] => 
                    [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:43:25
                    [post_modified_gmt] => 2020-08-06 07:43:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1162
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [186] => WP_Post Object
                (
                    [ID] => 1160
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:18:03
                    [post_date_gmt] => 2020-05-21 23:18:03
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:41:09
                    [post_modified_gmt] => 2020-08-06 07:41:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1160
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [187] => WP_Post Object
                (
                    [ID] => 1159
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:14:15
                    [post_date_gmt] => 2020-05-21 23:14:15
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:39:58
                    [post_modified_gmt] => 2020-08-06 07:39:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [188] => WP_Post Object
                (
                    [ID] => 1158
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:12:13
                    [post_date_gmt] => 2020-05-21 23:12:13
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:38:32
                    [post_modified_gmt] => 2020-08-06 07:38:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1158
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [189] => WP_Post Object
                (
                    [ID] => 1156
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:10:39
                    [post_date_gmt] => 2020-05-21 23:10:39
                    [post_content] => 
                    [post_title] => WHO Standard Framework Memorandum of Understanding
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-standard-framework-memorandum-of-understanding
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:36:26
                    [post_modified_gmt] => 2020-08-06 07:36:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1156
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [190] => WP_Post Object
                (
                    [ID] => 1155
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:09:39
                    [post_date_gmt] => 2020-05-21 23:09:39
                    [post_content] => 
                    [post_title] => WHO Template Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => template-collaboration-agreement-with-who
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:13:07
                    [post_modified_gmt] => 2020-08-06 08:13:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1155
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [191] => WP_Post Object
                (
                    [ID] => 1150
                    [post_author] => 6
                    [post_date] => 2020-05-21 22:53:25
                    [post_date_gmt] => 2020-05-21 22:53:25
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:15:03
                    [post_modified_gmt] => 2020-08-06 08:15:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1150
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [192] => WP_Post Object
                (
                    [ID] => 1147
                    [post_author] => 6
                    [post_date] => 2020-05-21 22:50:33
                    [post_date_gmt] => 2020-05-21 22:50:33
                    [post_content] => 
                    [post_title] => IMI 1 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-1-model-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:15:52
                    [post_modified_gmt] => 2020-08-06 08:15:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1147
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [193] => WP_Post Object
                (
                    [ID] => 1145
                    [post_author] => 6
                    [post_date] => 2020-05-21 22:48:08
                    [post_date_gmt] => 2020-05-21 22:48:08
                    [post_content] => 
                    [post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:17:09
                    [post_modified_gmt] => 2020-08-06 08:17:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1145
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [194] => WP_Post Object
                (
                    [ID] => 1143
                    [post_author] => 6
                    [post_date] => 2020-05-21 22:46:30
                    [post_date_gmt] => 2020-05-21 22:46:30
                    [post_content] => 
                    [post_title] => MPP License Agreement with Gilead
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-gilead-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:18:12
                    [post_modified_gmt] => 2020-08-06 08:18:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1143
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [195] => WP_Post Object
                (
                    [ID] => 1141
                    [post_author] => 6
                    [post_date] => 2020-05-21 22:43:46
                    [post_date_gmt] => 2020-05-21 22:43:46
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:19:21
                    [post_modified_gmt] => 2020-08-06 08:19:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1141
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [196] => WP_Post Object
                (
                    [ID] => 1140
                    [post_author] => 6
                    [post_date] => 2020-05-21 22:37:27
                    [post_date_gmt] => 2020-05-21 22:37:27
                    [post_content] => 
                    [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:21:40
                    [post_modified_gmt] => 2020-08-06 08:21:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1140
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [197] => WP_Post Object
                (
                    [ID] => 1139
                    [post_author] => 6
                    [post_date] => 2020-05-21 22:35:04
                    [post_date_gmt] => 2020-05-21 22:35:04
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:22:26
                    [post_modified_gmt] => 2020-08-06 08:22:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1139
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [198] => WP_Post Object
                (
                    [ID] => 1137
                    [post_author] => 6
                    [post_date] => 2020-05-21 22:22:50
                    [post_date_gmt] => 2020-05-21 22:22:50
                    [post_content] => 
                    [post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:25:03
                    [post_modified_gmt] => 2020-08-06 08:25:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1137
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [199] => WP_Post Object
                (
                    [ID] => 1135
                    [post_author] => 6
                    [post_date] => 2020-05-21 22:19:46
                    [post_date_gmt] => 2020-05-21 22:19:46
                    [post_content] => 
                    [post_title] => NIH Model License Agreement for Use by Non-Profit
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-model-license-agreement-for-use-by-non-profit
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:25:31
                    [post_modified_gmt] => 2020-08-06 08:25:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1135
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [200] => WP_Post Object
                (
                    [ID] => 1134
                    [post_author] => 6
                    [post_date] => 2020-05-21 22:00:36
                    [post_date_gmt] => 2020-05-21 22:00:36
                    [post_content] => 
                    [post_title] => CAVD Data & Materials Sharing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cavd-data-materials-sharing-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:25:48
                    [post_modified_gmt] => 2020-08-06 08:25:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1134
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [201] => WP_Post Object
                (
                    [ID] => 1132
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:58:10
                    [post_date_gmt] => 2020-05-21 21:58:10
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-12 15:04:08
                    [post_modified_gmt] => 2021-04-12 15:04:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1132
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [202] => WP_Post Object
                (
                    [ID] => 1131
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:56:27
                    [post_date_gmt] => 2020-05-21 21:56:27
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-%c2%a725-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:12:00
                    [post_modified_gmt] => 2020-08-06 08:12:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1131
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [203] => WP_Post Object
                (
                    [ID] => 1129
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:51:51
                    [post_date_gmt] => 2020-05-21 21:51:51
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement §25.2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:10:01
                    [post_modified_gmt] => 2020-08-06 08:10:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1129
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [204] => WP_Post Object
                (
                    [ID] => 1128
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:50:04
                    [post_date_gmt] => 2020-05-21 21:50:04
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:09:28
                    [post_modified_gmt] => 2020-08-06 08:09:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1128
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [205] => WP_Post Object
                (
                    [ID] => 1127
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:47:49
                    [post_date_gmt] => 2020-05-21 21:47:49
                    [post_content] => 
                    [post_title] => BU Startup Exclusive License
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bu-startup-exclusive-license
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:08:46
                    [post_modified_gmt] => 2020-08-06 08:08:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1127
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [206] => WP_Post Object
                (
                    [ID] => 1125
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:44:59
                    [post_date_gmt] => 2020-05-21 21:44:59
                    [post_content] => 
                    [post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:08:05
                    [post_modified_gmt] => 2020-08-06 08:08:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1125
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [207] => WP_Post Object
                (
                    [ID] => 1124
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:41:21
                    [post_date_gmt] => 2020-05-21 21:41:21
                    [post_content] => 
                    [post_title] => MPP Amended and Restated Sublicense and Technology Transfer Agreement under BMS-MPP License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-12 14:55:27
                    [post_modified_gmt] => 2021-04-12 14:55:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1124
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [208] => WP_Post Object
                (
                    [ID] => 1123
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:37:52
                    [post_date_gmt] => 2020-05-21 21:37:52
                    [post_content] => 
                    [post_title] => MPP License Agreement with ViiV on Dolutegravir for Adults
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:02:41
                    [post_modified_gmt] => 2020-08-06 08:02:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1123
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [209] => WP_Post Object
                (
                    [ID] => 1122
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:30:19
                    [post_date_gmt] => 2020-05-21 21:30:19
                    [post_content] => 
                    [post_title] => MPP License Agreement with BMS & Aurobindo Pharma Ltd.
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:02:05
                    [post_modified_gmt] => 2020-08-06 08:02:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1122
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [210] => WP_Post Object
                (
                    [ID] => 1120
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:28:37
                    [post_date_gmt] => 2020-05-21 21:28:37
                    [post_content] => 
                    [post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:00:43
                    [post_modified_gmt] => 2020-08-06 08:00:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1120
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [211] => WP_Post Object
                (
                    [ID] => 1118
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:24:00
                    [post_date_gmt] => 2020-05-21 21:24:00
                    [post_content] => 
                    [post_title] => MPP License Agreement with AbbVie (LPV r)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpps-license-agreement-with-abbvie
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:59:29
                    [post_modified_gmt] => 2020-08-06 07:59:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1118
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [212] => WP_Post Object
                (
                    [ID] => 1117
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:17:31
                    [post_date_gmt] => 2020-05-21 21:17:31
                    [post_content] => 
                    [post_title] => MPP License Agreement with University of Liverpool
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpps-license-agreement-with-university-of-liverpool
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:58:09
                    [post_modified_gmt] => 2020-08-06 07:58:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1117
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [213] => WP_Post Object
                (
                    [ID] => 1114
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:13:15
                    [post_date_gmt] => 2020-05-21 21:13:15
                    [post_content] => 
                    [post_title] => MPP License Agreement with Gilead
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-gilead
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:55:36
                    [post_modified_gmt] => 2020-08-06 07:55:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1114
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [214] => WP_Post Object
                (
                    [ID] => 1113
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:09:47
                    [post_date_gmt] => 2020-05-21 21:09:47
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:54:21
                    [post_modified_gmt] => 2020-08-06 07:54:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1113
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [215] => WP_Post Object
                (
                    [ID] => 1112
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:06:05
                    [post_date_gmt] => 2020-05-21 21:06:05
                    [post_content] => 
                    [post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:53:41
                    [post_modified_gmt] => 2020-08-06 07:53:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1112
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [216] => WP_Post Object
                (
                    [ID] => 1111
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:03:23
                    [post_date_gmt] => 2020-05-21 21:03:23
                    [post_content] => 
                    [post_title] => IMI 1 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-1-model-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:53:03
                    [post_modified_gmt] => 2020-08-06 07:53:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1111
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [217] => WP_Post Object
                (
                    [ID] => 1109
                    [post_author] => 6
                    [post_date] => 2020-05-21 21:01:18
                    [post_date_gmt] => 2020-05-21 21:01:18
                    [post_content] => 
                    [post_title] => CAVD Data & Materials Sharing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cavd-data-materials-sharing-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-04 04:28:44
                    [post_modified_gmt] => 2020-08-04 04:28:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1109
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [218] => WP_Post Object
                (
                    [ID] => 1108
                    [post_author] => 6
                    [post_date] => 2020-05-21 20:59:47
                    [post_date_gmt] => 2020-05-21 20:59:47
                    [post_content] => 
                    [post_title] => WHO Template Material Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-template-material-transfer-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:51:26
                    [post_modified_gmt] => 2020-08-06 07:51:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1108
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [219] => WP_Post Object
                (
                    [ID] => 1107
                    [post_author] => 6
                    [post_date] => 2020-05-21 20:57:25
                    [post_date_gmt] => 2020-05-21 20:57:25
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:50:28
                    [post_modified_gmt] => 2020-08-06 07:50:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1107
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [220] => WP_Post Object
                (
                    [ID] => 996
                    [post_author] => 7
                    [post_date] => 2020-05-18 19:58:18
                    [post_date_gmt] => 2020-05-18 19:58:18
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 07:49:31
                    [post_modified_gmt] => 2020-08-06 07:49:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [invalid_get] => 
    [is_text_search] => 
    [has_agreement_filters] => 
    [has_any_agreement_filter] => Array
        (
        )

    [found_agreements] => 
    [has_provision_filters] => 
    [found_provisions] => 1
    [lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
    [lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
    [lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
    [lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
    [lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
    [lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
    [issues_by_id:GHIAA2019\MapguideSearch:private] => Array
        (
            [46] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Access to medicines
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 1
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [91] => WP_Term Object
                (
                    [term_id] => 91
                    [name] => Access to results
                    [slug] => access-results
                    [term_group] => 0
                    [term_taxonomy_id] => 91
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 13
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [100] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable or reasonable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [55] => WP_Term Object
                (
                    [term_id] => 55
                    [name] => Annexes
                    [slug] => annexes
                    [term_group] => 0
                    [term_taxonomy_id] => 55
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [66] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit/revenue sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 3
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [53] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 1
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [58] => WP_Term Object
                (
                    [term_id] => 58
                    [name] => Commercialization strategy
                    [slug] => commercialization-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 58
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 55
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Annexes
                    [parent_slug] => annexes
                )

            [84] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 25
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [59] => WP_Term Object
                (
                    [term_id] => 59
                    [name] => Conflict of Interest
                    [slug] => conflict-of-interest
                    [term_group] => 0
                    [term_taxonomy_id] => 59
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 2
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [51] => WP_Term Object
                (
                    [term_id] => 51
                    [name] => Consortium structure & management
                    [slug] => consortium-structure
                    [term_group] => 0
                    [term_taxonomy_id] => 51
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 7
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [95] => WP_Term Object
                (
                    [term_id] => 95
                    [name] => Data & material sharing
                    [slug] => data-material-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 95
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [82] => WP_Term Object
                (
                    [term_id] => 82
                    [name] => Data management
                    [slug] => data-management
                    [term_group] => 0
                    [term_taxonomy_id] => 82
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [267] => WP_Term Object
                (
                    [term_id] => 267
                    [name] => Dispute resolution
                    [slug] => dispute-resolution
                    [term_group] => 0
                    [term_taxonomy_id] => 267
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 4
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [72] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effect of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [101] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Equitable access
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 15
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [83] => WP_Term Object
                (
                    [term_id] => 83
                    [name] => Exceptions and limitations to the confidentiality obligations
                    [slug] => exceptions-confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 83
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 7
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [93] => WP_Term Object
                (
                    [term_id] => 93
                    [name] => Exceptions or limitations to the IP ownership rules
                    [slug] => exceptions-ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 93
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 1
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [92] => WP_Term Object
                (
                    [term_id] => 92
                    [name] => Exploitation of results
                    [slug] => exploitation-results
                    [term_group] => 0
                    [term_taxonomy_id] => 92
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 11
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [103] => WP_Term Object
                (
                    [term_id] => 103
                    [name] => Funder step-in rights
                    [slug] => funder-step-in
                    [term_group] => 0
                    [term_taxonomy_id] => 103
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [57] => WP_Term Object
                (
                    [term_id] => 57
                    [name] => Global access plans
                    [slug] => global-access-plans
                    [term_group] => 0
                    [term_taxonomy_id] => 57
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 55
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Annexes
                    [parent_slug] => annexes
                )

            [80] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnity / indemnification
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [257] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [49] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Information sharing & data safety
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 3
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [109] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [48] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => IP ownership & licensing
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 1
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [50] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [79] => WP_Term Object
                (
                    [term_id] => 79
                    [name] => Limitation of liability/damage
                    [slug] => limitation-of-liability
                    [term_group] => 0
                    [term_taxonomy_id] => 79
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 17
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [85] => WP_Term Object
                (
                    [term_id] => 85
                    [name] => Material transfer
                    [slug] => material-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 85
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 4
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [98] => WP_Term Object
                (
                    [term_id] => 98
                    [name] => Open data
                    [slug] => open-data
                    [term_group] => 0
                    [term_taxonomy_id] => 98
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [97] => WP_Term Object
                (
                    [term_id] => 97
                    [name] => Open sciences
                    [slug] => open-sciences
                    [term_group] => 0
                    [term_taxonomy_id] => 97
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [47] => WP_Term Object
                (
                    [term_id] => 47
                    [name] => Open sciences & open data
                    [slug] => open-science
                    [term_group] => 0
                    [term_taxonomy_id] => 47
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [54] => WP_Term Object
                (
                    [term_id] => 54
                    [name] => Other
                    [slug] => other
                    [term_group] => 0
                    [term_taxonomy_id] => 54
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [102] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Outbreak preparedness
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [87] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of background IP
                    [slug] => ownership-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 10
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [89] => WP_Term Object
                (
                    [term_id] => 89
                    [name] => Ownership of results
                    [slug] => ownership-results
                    [term_group] => 0
                    [term_taxonomy_id] => 89
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 21
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [266] => WP_Term Object
                (
                    [term_id] => 266
                    [name] => Pandemic Products
                    [slug] => pandemic-products
                    [term_group] => 0
                    [term_taxonomy_id] => 266
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [104] => WP_Term Object
                (
                    [term_id] => 104
                    [name] => Policy considerations
                    [slug] => policy-considerations
                    [term_group] => 0
                    [term_taxonomy_id] => 104
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [90] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of results
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 10
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [107] => WP_Term Object
                (
                    [term_id] => 107
                    [name] => Public health licenses
                    [slug] => public-health-licenses
                    [term_group] => 0
                    [term_taxonomy_id] => 107
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 2
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [96] => WP_Term Object
                (
                    [term_id] => 96
                    [name] => Publication
                    [slug] => publication
                    [term_group] => 0
                    [term_taxonomy_id] => 96
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 9
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [56] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 55
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Annexes
                    [parent_slug] => annexes
                )

            [64] => WP_Term Object
                (
                    [term_id] => 64
                    [name] => Reporting
                    [slug] => reporting
                    [term_group] => 0
                    [term_taxonomy_id] => 64
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [81] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & Warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [69] => WP_Term Object
                (
                    [term_id] => 69
                    [name] => Risk sharing
                    [slug] => risk-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 69
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [70] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Royalties & payments
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [108] => WP_Term Object
                (
                    [term_id] => 108
                    [name] => Sublicenses
                    [slug] => sublicensee
                    [term_group] => 0
                    [term_taxonomy_id] => 108
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 2
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [268] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Supply/Purchase of Products
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 3
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [62] => WP_Term Object
                (
                    [term_id] => 62
                    [name] => Survival
                    [slug] => survival
                    [term_group] => 0
                    [term_taxonomy_id] => 62
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [86] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [52] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [76] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 7
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [74] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 7
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [88] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => Use of background IP
                    [slug] => use-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 20
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

        )

    [issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
        (
            [access-to-medicines] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Access to medicines
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 1
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [access-results] => WP_Term Object
                (
                    [term_id] => 91
                    [name] => Access to results
                    [slug] => access-results
                    [term_group] => 0
                    [term_taxonomy_id] => 91
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 13
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [pricing] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable or reasonable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [annexes] => WP_Term Object
                (
                    [term_id] => 55
                    [name] => Annexes
                    [slug] => annexes
                    [term_group] => 0
                    [term_taxonomy_id] => 55
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [benefit-revenue-sharing] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit/revenue sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 3
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [business-model] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 1
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [commercialization-strategy] => WP_Term Object
                (
                    [term_id] => 58
                    [name] => Commercialization strategy
                    [slug] => commercialization-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 58
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 55
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Annexes
                    [parent_slug] => annexes
                )

            [confidentiality] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 25
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [conflict-of-interest] => WP_Term Object
                (
                    [term_id] => 59
                    [name] => Conflict of Interest
                    [slug] => conflict-of-interest
                    [term_group] => 0
                    [term_taxonomy_id] => 59
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 2
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [consortium-structure] => WP_Term Object
                (
                    [term_id] => 51
                    [name] => Consortium structure & management
                    [slug] => consortium-structure
                    [term_group] => 0
                    [term_taxonomy_id] => 51
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 7
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [data-material-sharing] => WP_Term Object
                (
                    [term_id] => 95
                    [name] => Data & material sharing
                    [slug] => data-material-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 95
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [data-management] => WP_Term Object
                (
                    [term_id] => 82
                    [name] => Data management
                    [slug] => data-management
                    [term_group] => 0
                    [term_taxonomy_id] => 82
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [dispute-resolution] => WP_Term Object
                (
                    [term_id] => 267
                    [name] => Dispute resolution
                    [slug] => dispute-resolution
                    [term_group] => 0
                    [term_taxonomy_id] => 267
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 4
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [effect-of-termination] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effect of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [equitable-access] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Equitable access
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 15
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [exceptions-confidentiality] => WP_Term Object
                (
                    [term_id] => 83
                    [name] => Exceptions and limitations to the confidentiality obligations
                    [slug] => exceptions-confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 83
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 7
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [exceptions-ip-ownership] => WP_Term Object
                (
                    [term_id] => 93
                    [name] => Exceptions or limitations to the IP ownership rules
                    [slug] => exceptions-ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 93
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 1
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [exploitation-results] => WP_Term Object
                (
                    [term_id] => 92
                    [name] => Exploitation of results
                    [slug] => exploitation-results
                    [term_group] => 0
                    [term_taxonomy_id] => 92
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 11
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [funder-step-in] => WP_Term Object
                (
                    [term_id] => 103
                    [name] => Funder step-in rights
                    [slug] => funder-step-in
                    [term_group] => 0
                    [term_taxonomy_id] => 103
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [global-access-plans] => WP_Term Object
                (
                    [term_id] => 57
                    [name] => Global access plans
                    [slug] => global-access-plans
                    [term_group] => 0
                    [term_taxonomy_id] => 57
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 55
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Annexes
                    [parent_slug] => annexes
                )

            [indemnity] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnity / indemnification
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [information-sharing-information-sharing] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [information-sharing] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Information sharing & data safety
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 3
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [insurance] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [ip-ownership] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => IP ownership & licensing
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 1
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [liability] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [limitation-of-liability] => WP_Term Object
                (
                    [term_id] => 79
                    [name] => Limitation of liability/damage
                    [slug] => limitation-of-liability
                    [term_group] => 0
                    [term_taxonomy_id] => 79
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 17
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [material-transfer] => WP_Term Object
                (
                    [term_id] => 85
                    [name] => Material transfer
                    [slug] => material-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 85
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 4
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [open-data] => WP_Term Object
                (
                    [term_id] => 98
                    [name] => Open data
                    [slug] => open-data
                    [term_group] => 0
                    [term_taxonomy_id] => 98
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [open-sciences] => WP_Term Object
                (
                    [term_id] => 97
                    [name] => Open sciences
                    [slug] => open-sciences
                    [term_group] => 0
                    [term_taxonomy_id] => 97
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [open-science] => WP_Term Object
                (
                    [term_id] => 47
                    [name] => Open sciences & open data
                    [slug] => open-science
                    [term_group] => 0
                    [term_taxonomy_id] => 47
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [other] => WP_Term Object
                (
                    [term_id] => 54
                    [name] => Other
                    [slug] => other
                    [term_group] => 0
                    [term_taxonomy_id] => 54
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [outbreak-preparedness] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Outbreak preparedness
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [ownership-background-ip] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of background IP
                    [slug] => ownership-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 10
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [ownership-results] => WP_Term Object
                (
                    [term_id] => 89
                    [name] => Ownership of results
                    [slug] => ownership-results
                    [term_group] => 0
                    [term_taxonomy_id] => 89
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 21
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [pandemic-products] => WP_Term Object
                (
                    [term_id] => 266
                    [name] => Pandemic Products
                    [slug] => pandemic-products
                    [term_group] => 0
                    [term_taxonomy_id] => 266
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [policy-considerations] => WP_Term Object
                (
                    [term_id] => 104
                    [name] => Policy considerations
                    [slug] => policy-considerations
                    [term_group] => 0
                    [term_taxonomy_id] => 104
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [protection-results] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of results
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 10
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [public-health-licenses] => WP_Term Object
                (
                    [term_id] => 107
                    [name] => Public health licenses
                    [slug] => public-health-licenses
                    [term_group] => 0
                    [term_taxonomy_id] => 107
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 2
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [publication] => WP_Term Object
                (
                    [term_id] => 96
                    [name] => Publication
                    [slug] => publication
                    [term_group] => 0
                    [term_taxonomy_id] => 96
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 9
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [regulatory-strategy] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 55
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Annexes
                    [parent_slug] => annexes
                )

            [reporting] => WP_Term Object
                (
                    [term_id] => 64
                    [name] => Reporting
                    [slug] => reporting
                    [term_group] => 0
                    [term_taxonomy_id] => 64
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [warranties] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & Warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [risk-sharing] => WP_Term Object
                (
                    [term_id] => 69
                    [name] => Risk sharing
                    [slug] => risk-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 69
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [royalties-and-payments] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Royalties & payments
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [sublicensee] => WP_Term Object
                (
                    [term_id] => 108
                    [name] => Sublicenses
                    [slug] => sublicensee
                    [term_group] => 0
                    [term_taxonomy_id] => 108
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 2
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [supply-purchase-of-products] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Supply/Purchase of Products
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 3
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [survival] => WP_Term Object
                (
                    [term_id] => 62
                    [name] => Survival
                    [slug] => survival
                    [term_group] => 0
                    [term_taxonomy_id] => 62
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [technology-transfer] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [term-and-termination] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [term-of-agreement] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 7
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [termination-and-withdrawal] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 7
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [use-background-ip] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => Use of background IP
                    [slug] => use-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 20
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

        )

    [filter_issues:GHIAA2019\MapguideSearch:private] => Array
        (
        )

)